{
  "state": "florida",
  "path": "title-chapter-0893/chapter-chapter-0893",
  "sections": [
    {
      "id": "section-89301short",
      "number": "893.01",
      "heading": "Short title.893.015Statutory references",
      "text": "893.02Definitions.893.03Standards and schedules.893.0301Death resulting from apparent drug overdose; reporting requirements.893.031Industrial exceptions to controlled substance scheduling.893.033Listed chemicals.893.035Control of new substances; findings of fact; de",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-893015statutory",
      "number": "893.015",
      "heading": "Statutory references.",
      "text": "893.015 Statutory references.—The purpose of this chapter is to comprehensively address drug abuse prevention and control in this state. To this end, unless expressly provided otherwise, a reference in any section of the Florida Statutes to chapter 893 or to any section or portion of a section of chapter 893 includes all subsequent amendments to chapter 893 or to the referenced section or portion of a section. History.—s. 3, ch. 2017-107; s. 2, ch. 2017-110. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d188bc29acf',t:'MTc3MDg4MjU1OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-015/"
    },
    {
      "id": "section-89302definitions",
      "number": "893.02",
      "heading": "Definitions",
      "text": "893.02 Definitions.—The following words and phrases as used in this chapter shall have the following meanings, unless the context otherwise requires:",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-02/"
    },
    {
      "id": "section-89303standards",
      "number": "893.03",
      "heading": "Standards and schedules.",
      "text": "893.03 Standards and schedules.—The substances enumerated in this section are controlled by this chapter. The controlled substances listed or to be listed in Schedules I, II, III, IV, and V are included by whatever official, common, usual, chemical, trade name, or class designated. The provisions of this section shall not be construed to include within any of the schedules contained in this section any excluded drugs listed within the purview of 21 C.F.R. s. 1308.22, styled “Excluded Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt Anabolic Steroid Products.” (1) SCHEDULE I.—A substance in Schedule I has a high potential for abuse and has no currently accepted medical use in treatment in the United States and in its use under medical supervision does not meet accepted safety standards. The following substances are controlled in Schedule I: (a) Unless specifically excepted or unless listed in another schedule, any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: 1. Acetyl-alpha-methylfentanyl. 2. Acetylmethadol. 3. Allylprodine. 4. Alphacetylmethadol (except levo-alphacetylmethadol, also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM). 5. Alphamethadol. 6. Alpha-methylfentanyl (N-[1-(alpha-methyl-betaphenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine). 7. Alpha-methylthiofentanyl. 8. Alphameprodine. 9. Benzethidine. 10. Benzylfentanyl. 11. Betacetylmethadol. 12. Beta-hydroxyfentanyl. 13. Beta-hydroxy-3-methylfentanyl. 14. Betameprodine. 15. Betamethadol. 16. Betaprodine. 17. Clonitazene. 18. Dextromoramide. 19. Diampromide. 20. Diethylthiambutene. 21. Difenoxin. 22. Dimenoxadol. 23. Dimepheptanol. 24. Dimethylthiambutene. 25. Dioxaphetyl butyrate. 26. Dipipanone. 27. Ethylmethylthiambutene. 28. Etonitazene. 29. Etoxeridine. 30. Flunitrazepam. 31. Furethidine. 32. Hydroxypethidine. 33. Ketobemidone. 34. Levomoramide. 35. Levophenacylmorphan. 36. Desmethylprodine (1-Methyl-4-Phenyl-4-Propionoxypiperidine). 37. 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide). 38. 3-Methylthiofentanyl. 39. Morpheridine. 40. Noracymethadol. 41. Norlevorphanol. 42. Normethadone. 43. Norpipanone. 44. Para-Fluorofentanyl. 45. Phenadoxone. 46. Phenampromide. 47. Phenomorphan. 48. Phenoperidine. 49. PEPAP (1-(2-Phenylethyl)-4-Phenyl-4-Acetyloxypiperidine). 50. Piritramide. 51. Proheptazine. 52. Properidine. 53. Propiram. 54. Racemoramide. 55. Thenylfentanyl. 56. Thiofentanyl. 57. Tianeptine. 58. Tilidine. 59. Trimeperidine. 60. Acetylfentanyl. 61. Butyrylfentanyl. 62. Beta-Hydroxythiofentanyl. 63. Fentanyl derivatives. Unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations containing a 4-anilidopiperidine structure: a. With or without substitution at the carbonyl of the aniline moiety with alkyl, alkenyl, carboalkoxy, cycloalkyl, methoxyalkyl, cyanoalkyl, or aryl groups, or furanyl, dihydrofuranyl, benzyl moiety, or rings containing heteroatoms sulfur, oxygen, or nitrogen; b. With or without substitution at the piperidine amino moiety with a phenethyl, benzyl, alkylaryl (including heteroaromatics), alkyltetrazolyl ring, or an alkyl or carbomethoxy group, whether or not further substituted in the ring or group; c. With or without substitution or addition to the piperdine ring to any extent with one or more methyl, carbomethoxy, methoxy, methoxymethyl, aryl, allyl, or ester groups; d. With or without substitution of one or more hydrogen atoms for halogens, or methyl, alkyl, or methoxy groups, in the aromatic ring of the anilide moiety; e. With or without substitution at the alpha or beta position of the piperidine ring with alkyl, hydroxyl, or methoxy groups; f. With or without substitution of the benzene ring of the anilide moiety for an aromatic heterocycle; and g. With or without substitution of the piperidine ring for a pyrrolidine ring, perhydroazepine ring, or azepine ring; excluding, Alfentanil, Carfentanil, Fentanyl, and Sufentanil; including, but not limited to: (I) Acetyl-alpha-methylfentanyl. (II) Alpha-methylfentanyl (N-[1-(alpha-methyl-betaphenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine). (III) Alpha-methylthiofentanyl. (IV) Benzylfentanyl. (V) Beta-hydroxyfentanyl. (VI) Beta-hydroxy-3-methylfentanyl. (VII) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide). (VIII) 3-Methylthiofentanyl. (IX) Para-Fluorofentanyl. (X) Thenylfentanyl or Thienyl fentanyl. (XI) Thiofentanyl. (XII) Acetylfentanyl. (XIII) Butyrylfentanyl. (XIV) Beta-Hydroxythiofentanyl. (XV) Lofentanil. (XVI) Ocfentanil. (XVII) Ohmfentanyl. (XVIII) Benzodioxolefentanyl. (XIX) Furanyl fentanyl. (XX) Pentanoyl fentanyl. (XXI) Cyclopentyl fentanyl. (XXII) Isobutyryl fentanyl. (XXIII) Remifentanil. 64. Nitazene derivatives. Unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations containing a benzimidazole ring with an ethylamine substitution at the 1-position and a benzyl ring substitution at the 2-position structure: a. With or without substitution on the benzimidazole ring with alkyl, alkoxy, carboalkoxy, amino, nitro, or aryl groups, or halogens; b. With or without substitution at the ethylamine amino moiety with alkyl, dialkyl, acetyl, or benzyl groups, whether or not further substituted in the ring system; c. With or without inclusion of the ethylamine amino moiety in a cyclic structure; d. With or without substitution of the benzyl ring; or e. With or without replacement of the benzyl ring with an aromatic ring, including, but not limited to: (I) Butonitazene. (II) Clonitazene. (III) Etodesnitazene. (IV) Etonitazene. (V) Flunitazene. (VI) Isotodesnitazene. (VII) Isotonitazene. (VIII) Metodesnitazene. (IX) Metonitazene. (X) Nitazene. (XI) N-Desethyl Etonitazene. (XII) N-Desethyl Isotonitazene. (XIII) N-Piperidino Etonitazene. (XIV) N-Pyrrolidino Etonitazene. (XV) Protonitazene. (b) Unless specifically excepted or unless listed in another schedule, any of the following substances, their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: 1. Acetorphine. 2. Acetyldihydrocodeine. 3. Benzylmorphine. 4. Codeine methylbromide. 5. Codeine-N-Oxide. 6. Cyprenorphine. 7. Desomorphine. 8. Dihydromorphine. 9. Drotebanol. 10. Etorphine (except hydrochloride salt). 11. Heroin. 12. Hydromorphinol. 13. Methyldesorphine. 14. Methyldihydromorphine. 15. Monoacetylmorphine. 16. Morphine methylbromide. 17. Morphine methylsulfonate. 18. Morphine-N-Oxide. 19. Myrophine. 20. Nicocodine. 21. Nicomorphine. 22. Normorphine. 23. Pholcodine. 24. Thebacon. (c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or that contains any of their salts, isomers, including optical, positional, or geometric isomers, homologues, nitrogen-heterocyclic analogs, esters, ethers, and salts of isomers, homologues, nitrogen-heterocyclic analogs, esters, or ethers, if the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation or class description: 1. Alpha-Ethyltryptamine. 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-oxazoline). 3. Aminorex (2-Amino-5-phenyl-2-oxazoline). 4. DOB (4-Bromo-2,5-dimethoxyamphetamine). 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine). 6. Bufotenine. 7. Cannabis. 8. Cathinone. 9. DET (Diethyltryptamine). 10. 2,5-Dimethoxyamphetamine. 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine). 12. DMT (Dimethyltryptamine). 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog of phencyclidine). 14. JB-318 (N-Ethyl-3-piperidyl benzilate). 15. N-Ethylamphetamine. 16. Fenethylline. 17. 3,4-Methylenedioxy-N-hydroxyamphetamine. 18. Ibogaine. 19. LSD (Lysergic acid diethylamide). 20. Mescaline. 21. Methcathinone. 22. 5-Methoxy-3,4-methylenedioxyamphetamine. 23. PMA (4-Methoxyamphetamine). 24. PMMA (4-Methoxymethamphetamine). 25. DOM (4-Methyl-2,5-dimethoxyamphetamine). 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine). 27. MDA (3,4-Methylenedioxyamphetamine). 28. JB-336 (N-Methyl-3-piperidyl benzilate). 29. N,N-Dimethylamphetamine. 30. Parahexyl. 31. Peyote. 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine analog of phencyclidine). 33. Psilocybin. 34. Psilocyn. 35. Salvia divinorum, except for any drug product approved by the United States Food and Drug Administration which contains Salvia divinorum or its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, if the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. 36. Salvinorin A, except for any drug product approved by the United States Food and Drug Administration which contains Salvinorin A or its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, if the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. 37. Xylazine. 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene analog of phencyclidine). 39. 3,4,5-Trimethoxyamphetamine. 40. Methylone (3,4-Methylenedioxymethcathinone). 41. MDPV (3,4-Methylenedioxypyrovalerone). 42. Methylmethcathinone. 43. Methoxymethcathinone. 44. Fluoromethcathinone. 45. Methylethcathinone. 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol) and its dimethyloctyl (C8) homologue. 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol]. 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole). 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole). 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole). 51. BZP (Benzylpiperazine). 52. Fluorophenylpiperazine. 53. Methylphenylpiperazine. 54. Chlorophenylpiperazine. 55. Methoxyphenylpiperazine. 56. DBZP (1,4-Dibenzylpiperazine). 57. TFMPP (Trifluoromethylphenylpiperazine). 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-Methylenedioxy-N-methylbutanamine). 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine). 60. 5-Hydroxy-N-methyltryptamine. 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine). 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine). 63. Methyltryptamine. 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine). 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine). 66. Tyramine (4-Hydroxyphenethylamine). 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine). 68. DiPT (N,N-Diisopropyltryptamine). 69. DPT (N,N-Dipropyltryptamine). 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine). 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine). 72. DOI (4-Iodo-2,5-dimethoxyamphetamine). 73. DOC (4-Chloro-2,5-dimethoxyamphetamine). 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine). 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine). 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine). 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine). 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine). 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine). 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine). 81. Butylone (3,4-Methylenedioxy-alpha-methylaminobutyrophenone). 82. Ethcathinone. 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone). 84. Naphyrone (Naphthylpyrovalerone). 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone). 86. 3,4-Methylenedioxy-N,N-diethylcathinone. 87. 3,4-Methylenedioxy-propiophenone. 88. 3,4-Methylenedioxy-alpha-bromopropiophenone. 89. 3,4-Methylenedioxy-propiophenone-2-oxime. 90. 3,4-Methylenedioxy-N-acetylcathinone. 91. 3,4-Methylenedioxy-N-acetylmethcathinone. 92. 3,4-Methylenedioxy-N-acetylethcathinone. 93. Bromomethcathinone. 94. Buphedrone (alpha-Methylamino-butyrophenone). 95. Eutylone (3,4-Methylenedioxy-alpha-ethylaminobutyrophenone). 96. Dimethylcathinone. 97. Dimethylmethcathinone. 98. Pentylone (3,4-Methylenedioxy-alpha-methylaminovalerophenone). 99. MDPPP (3,4-Methylenedioxy-alpha-pyrrolidinopropiophenone). 100. MDPBP (3,4-Methylenedioxy-alpha-pyrrolidinobutyrophenone). 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone). 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone). 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP (Benocyclidine). 104. F-MABP (Fluoromethylaminobutyrophenone). 105. MeO-PBP (Methoxypyrrolidinobutyrophenone). 106. Et-PBP (Ethylpyrrolidinobutyrophenone). 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone). 108. Me-EABP (Methylethylaminobutyrophenone). 109. Etizolam. 110. PPP (Pyrrolidinopropiophenone). 111. PBP (Pyrrolidinobutyrophenone). 112. PVP (Pyrrolidinovalerophenone) or (Pyrrolidinopentiophenone). 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone). 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole). 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole). 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole). 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole). 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole). 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole). 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole). 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole). 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole). 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole). 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole). 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole). 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole). 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole). 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole). 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol). 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol). 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione). 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene). 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-undecanamide). 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-undecanamide). 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-methyloctan-2-yl)phenol). 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole). 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole). 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole). 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole). 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone). 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone). 143. Pentedrone (alpha-Methylaminovalerophenone). 144. Fluoroamphetamine. 145. Fluoromethamphetamine. 146. Methoxetamine. 147. Methiopropamine. 148. Methylbuphedrone (Methyl-alpha-methylaminobutyrophenone). 149. APB ((2-Aminopropyl)benzofuran). 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran). 151. UR-144 (1-Pentyl-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide). 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole). 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-carboxamide). 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)-cyclohexylcarbamate). 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester). 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one). 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine). 161. 2C-H (2,5-Dimethoxyphenethylamine). 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine). 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine). 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). 165. MDMA (3,4-Methylenedioxymethamphetamine). 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate). 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-carboxylate). 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-carboxylate). 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-3-carboxamide). 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide). 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide). 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide). 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(fluoropentyl)indole-3-carboxamide). 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide). 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-carboxylate). 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-3-carboxamide). 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide). 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole). 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol). 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol). 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol). 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol). 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol). 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione). 187. MAPB ((2-Methylaminopropyl)benzofuran). 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine). 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine). 190. Synthetic Cannabinoids.—Unless specifically excepted or unless listed in another schedule or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation that contains any quantity of a synthetic cannabinoid found to be in any of the following chemical class descriptions, or homologues, nitrogen-heterocyclic analogs, isomers (including optical, positional, or geometric), esters, ethers, salts, and salts of homologues, nitrogen-heterocyclic analogs, isomers, esters, or ethers, whenever the existence of such homologues, nitrogen-heterocyclic analogs, isomers, esters, ethers, salts, and salts of isomers, esters, or ethers is possible within the specific chemical class or designation. Since nomenclature of these synthetically produced cannabinoids is not internationally standardized and may continually evolve, these structures or the compounds of these structures shall be included under this subparagraph, regardless of their specific numerical designation of atomic positions covered, if it can be determined through a recognized method of scientific testing or analysis that the substance contains properties that fit within one or more of the following categories: a. Tetrahydrocannabinols.—Any tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, the synthetic equivalents of the substances contained in the plant or in the resinous extracts of the genus Cannabis, or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity, including, but not limited to, Delta 9 tetrahydrocannabinols and their optical isomers, Delta 8 tetrahydrocannabinols and their optical isomers, Delta 6a,10a tetrahydrocannabinols and their optical isomers, or any compound containing a tetrahydrobenzo[c]chromene structure with substitution at either or both the 3-position or 9-position, with or without substitution at the 1-position with hydroxyl or alkoxy groups, including, but not limited to: (I) Tetrahydrocannabinol. (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol). (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol). (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3-dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol). (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol). (X) Parahexyl. b. Naphthoylindoles, Naphthoylindazoles, Naphthoylcarbazoles, Naphthylmethylindoles, Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any compound containing a naphthoylindole, naphthoylindazole, naphthoylcarbazole, naphthylmethylindole, naphthylmethylindazole, or naphthylmethylcarbazole structure, with or without substitution on the indole, indazole, or carbazole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to: (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole). (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-naphthoyl)indole). (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole). (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole). (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole). (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole). (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole). (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole). (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole). (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole). (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole). (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole). (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole). (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole). (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole). (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole). (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-naphthoyl)indole). (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole). (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole). (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole). (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole). (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1-naphthylmethyl]indole). (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1-naphthoyl)indole). (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1-naphthoyl)indole). (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole). (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole). (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole). (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole). (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole). (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole). (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1-naphthoyl)indole). (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-naphthoyl)indole). (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole). (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-naphthoyl)indole). (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-naphthoyl)indole). (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole). (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole). (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-naphthoyl)indole). (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole). (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole). (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-naphthoyl)carbazole). c. Naphthoylpyrroles.—Any compound containing a naphthoylpyrrole structure, with or without substitution on the pyrrole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to: (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole). (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole). (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole). (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole). (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole). (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-naphthoyl)pyrrole). (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-naphthoyl)pyrrole). (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-naphthoyl)pyrrole). (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-naphthoyl)pyrrole). (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole). d. Naphthylmethylenindenes.—Any compound containing a naphthylmethylenindene structure, with or without substitution at the 3-position of the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to, JWH-176 (3-Pentyl-1-(naphthylmethylene)indene). e. Phenylacetylindoles and Phenylacetylindazoles.—Any compound containing a phenylacetylindole or phenylacetylindazole structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the phenyl ring to any extent, including, but not limited to: (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole). (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole). (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole). (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole). (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole). (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole). (VII) Cannabipiperidiethanone. (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole). f. Cyclohexylphenols.—Any compound containing a cyclohexylphenol structure, with or without substitution at the 5-position of the phenolic ring to any extent, whether or not substituted on the cyclohexyl ring to any extent, including, but not limited to: (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol). (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8) homologue). (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-methyloctan-2-yl)phenol). g. Benzoylindoles and Benzoylindazoles.—Any compound containing a benzoylindole or benzoylindazole structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the phenyl ring to any extent, including, but not limited to: (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole). (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole). (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-iodo-5-nitrobenzoyl)indole). (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole). (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole). (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole). (VII) RCS-4 C4 homologue (1-Butyl-3-(4-methoxybenzoyl)indole). (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-3-(4-methoxybenzoyl)indole). h. Tetramethylcyclopropanoylindoles and Tetramethylcyclopropanoylindazoles.—Any compound containing a tetramethylcyclopropanoylindole or tetramethylcyclopropanoylindazole structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the tetramethylcyclopropyl group to any extent, including, but not limited to: (I) UR-144 (1-Pentyl-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indazole). (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-tetramethylcyclopropanoyl)indole). i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole carboxamides, and Adamantylindazole carboxamides.—Any compound containing an adamantoyl indole, adamantoyl indazole, adamantyl indole carboxamide, or adamantyl indazole carboxamide structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent, including, but not limited to: (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide). (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-3-carboxamide). (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-carboxamide). (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-adamantoyl)indole). (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole). (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide). (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-adamantoyl)indole). j. Quinolinylindolecarboxylates, Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides, and Quinolinylindazolecarboxamides.—Any compound containing a quinolinylindole carboxylate, quinolinylindazole carboxylate, isoquinolinylindole carboxylate, isoquinolinylindazole carboxylate, quinolinylindole carboxamide, quinolinylindazole carboxamide, isoquinolinylindole carboxamide, or isoquinolinylindazole carboxamide structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the quinoline or isoquinoline ring to any extent, including, but not limited to: (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate). (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-carboxylate). (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-carboxylate). (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-carboxylate). (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate). (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole-3-carboxylate). (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole-3-carboxylate). (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide). (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3-carboxamide). k. Naphthylindolecarboxylates and Naphthylindazolecarboxylates.—Any compound containing a naphthylindole carboxylate or naphthylindazole carboxylate structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to: (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-carboxylate). (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-carboxylate). (III) Fluoro SDB-005 (1-Naphthalenyl 1-(fluoropentyl)indazole-3-carboxylate). (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-carboxylate). (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-carboxylate). l. Naphthylindole carboxamides and Naphthylindazole carboxamides.—Any compound containing a naphthylindole carboxamide or naphthylindazole carboxamide structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to: (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide). (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-3-carboxamide). (III) Chloro-NNEI (N-Naphthalen-1-yl 1-(chloropentyl)indole-3-carboxamide). (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-carboxamide). (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-(fluoropentyl)indazole-3-carboxamide). m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl indazole carboxamides, Alkylcarbonyl indole carboxylates, and Alkylcarbonyl indazole carboxylates.—Any compound containing an alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an indole carboxamide, indazole carboxamide, indole carboxylate, or indazole carboxylate, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the alkylcarbonyl group to any extent, including, but not limited to: (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindole-3-carboxamide). (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(fluoropentyl)indole-3-carboxamide). (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(fluoropentyl)indole-3-carboxamide). (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide). (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide). (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide). (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide). (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide). (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide). (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide). (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide). (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide). (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide). (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide). (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide). (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide). (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide). (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide). (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)indole-3-carboxamide). (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide). (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide). (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide). (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate). n. Cumylindolecarboxamides and Cumylindazolecarboxamides.—Any compound containing a N-(2-phenylpropan-2-yl) indole carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the phenyl ring of the cumyl group to any extent, including, but not limited to: (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-carboxamide). (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-(fluoropentyl)indole-3-carboxamide). o. Other Synthetic Cannabinoids.—Any material, compound, mixture, or preparation that contains any quantity of a Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.: (I) With or without modification or replacement of a carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage between either two core rings, or linkage between a core ring and group structure, with or without the addition of a carbon or replacement of a carbon; (II) With or without replacement of a core ring or group structure, whether or not substituted on the ring or group structures to any extent; and (III) Is a cannabinoid receptor agonist, unless specifically excepted or unless listed in another schedule or contained within a pharmaceutical product approved by the United States Food and Drug Administration. 191. Substituted Cathinones.—Unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations: a. Any compound containing a 2-amino-1-phenyl-1-propanone structure; b. Any compound containing a 2-amino-1-naphthyl-1-propanone structure; or c. Any compound containing a 2-amino-1-thiophenyl-1-propanone structure, whether or not the compound is further modified: (I) With or without substitution on the ring system to any extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy, haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide substituents; (II) With or without substitution at the 3-propanone position with an alkyl substituent or removal of the methyl group at the 3-propanone position; (III) With or without substitution at the 2-amino nitrogen atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or not further substituted in the ring system; or (IV) With or without inclusion of the 2-amino nitrogen atom in a cyclic structure, including, but not limited to: (A) Methcathinone. (B) Ethcathinone. (C) Methylone (3,4-Methylenedioxymethcathinone). (D) 2,3-Methylenedioxymethcathinone. (E) MDPV (3,4-Methylenedioxypyrovalerone). (F) Methylmethcathinone. (G) Methoxymethcathinone. (H) Fluoromethcathinone. (I) Methylethcathinone. (J) Butylone (3,4-Methylenedioxy-alpha-methylaminobutyrophenone). (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone). (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone). (M) Naphyrone (Naphthylpyrovalerone). (N) Bromomethcathinone. (O) Buphedrone (alpha-Methylaminobutyrophenone). (P) Eutylone (3,4-Methylenedioxy-alpha-ethylaminobutyrophenone). (Q) Dimethylcathinone. (R) Dimethylmethcathinone. (S) Pentylone (3,4-Methylenedioxy-alpha-methylaminovalerophenone). (T) Pentedrone (alpha-Methylaminovalerophenone). (U) MDPPP (3,4-Methylenedioxy-alpha-pyrrolidinopropiophenone). (V) MDPBP (3,4-Methylenedioxy-alpha-pyrrolidinobutyrophenone). (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone). (X) PPP (Pyrrolidinopropiophenone). (Y) PVP (Pyrrolidinovalerophenone) or (Pyrrolidinopentiophenone). (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone). (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone). (BB) F-MABP (Fluoromethylaminobutyrophenone). (CC) Me-EABP (Methylethylaminobutyrophenone). (DD) PBP (Pyrrolidinobutyrophenone). (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone). (FF) Et-PBP (Ethylpyrrolidinobutyrophenone). (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone). (HH) Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone). (II) 3,4-Methylenedioxy-N,N-diethylcathinone. (JJ) 3,4-Methylenedioxy-N-acetylcathinone. (KK) 3,4-Methylenedioxy-N-acetylmethcathinone. (LL) 3,4-Methylenedioxy-N-acetylethcathinone. (MM) Methylbuphedrone (Methyl-alpha-methylaminobutyrophenone). (NN) Methyl-alpha-methylaminohexanophenone. (OO) N-Ethyl-N-methylcathinone. (PP) PHP (Pyrrolidinohexanophenone). (QQ) PV8 (Pyrrolidinoheptanophenone). (RR) Chloromethcathinone. (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone. 192. Substituted Phenethylamines.—Unless specifically excepted or unless listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations, any compound containing a phenethylamine structure, without a beta-keto group, and without a benzyl group attached to the amine group, whether or not the compound is further modified with or without substitution on the phenyl ring to any extent with alkyl, alkylthio, nitro, alkoxy, thio, halide, fused alkylenedioxy, fused furan, fused benzofuran, fused dihydrofuran, or fused tetrahydropyran substituents, whether or not further substituted on a ring to any extent, with or without substitution at the alpha or beta position by any alkyl substituent, with or without substitution at the nitrogen atom, and with or without inclusion of the 2-amino nitrogen atom in a cyclic structure, including, but not limited to: a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine). b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine). c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine). d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine). e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine). f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine). g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine). h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine). i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine). j. 2C-H (2,5-Dimethoxyphenethylamine). k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine). l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine). m. MDMA (3,4-Methylenedioxymethamphetamine). n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-Methylenedioxy-N-methylbutanamine). o. MDA (3,4-Methylenedioxyamphetamine). p. 2,5-Dimethoxyamphetamine. q. Fluoroamphetamine. r. Fluoromethamphetamine. s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine). t. DOB (4-Bromo-2,5-dimethoxyamphetamine). u. DOC (4-Chloro-2,5-dimethoxyamphetamine). v. DOET (4-Ethyl-2,5-dimethoxyamphetamine). w. DOI (4-Iodo-2,5-dimethoxyamphetamine). x. DOM (4-Methyl-2,5-dimethoxyamphetamine). y. PMA (4-Methoxyamphetamine). z. N-Ethylamphetamine. aa. 3,4-Methylenedioxy-N-hydroxyamphetamine. bb. 5-Methoxy-3,4-methylenedioxyamphetamine. cc. PMMA (4-Methoxymethamphetamine). dd. N,N-Dimethylamphetamine. ee. 3,4,5-Trimethoxyamphetamine. ff. 4-APB (4-(2-Aminopropyl)benzofuran). gg. 5-APB (5-(2-Aminopropyl)benzofuran). hh. 6-APB (6-(2-Aminopropyl)benzofuran). ii. 7-APB (7-(2-Aminopropyl)benzofuran). jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran). kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran). ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran). mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran). nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran). oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran). pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran). qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran). rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran). ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-dihydrobenzofuran), which does not include phenethylamine, mescaline as described in subparagraph 20., substituted cathinones as described in subparagraph 191., N-Benzyl phenethylamine compounds as described in subparagraph 193., or methamphetamine as described in subparagraph (2)(c)5. 193. N-Benzyl Phenethylamine Compounds.—Unless specifically excepted or unless listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations, any compound containing a phenethylamine structure without a beta-keto group, with substitution on the nitrogen atom of the amino group with a benzyl substituent, with or without substitution on the phenyl or benzyl ring to any extent with alkyl, alkoxy, thio, alkylthio, halide, fused alkylenedioxy, fused furan, fused benzofuran, or fused tetrahydropyran substituents, whether or not further substituted on a ring to any extent, with or without substitution at the alpha position by any alkyl substituent, including, but not limited to: a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-hydroxybenzyl)]phenethylamine). c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-fluorobenzyl)]phenethylamine). d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-methylenedioxybenzyl)]phenethylamine). e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-hydroxybenzyl)]phenethylamine). g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-fluorobenzyl)]phenethylamine). h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-methylenedioxybenzyl)]phenethylamine). i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-hydroxybenzyl)]phenethylamine). n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-fluorobenzyl)]phenethylamine). o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-methylenedioxybenzyl)]phenethylamine). p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-methoxybenzyl)]phenethylamine). q. 25H-NBOH (2,5-Dimethoxy-[N-(2-hydroxybenzyl)]phenethylamine). r. 25H-NBF (2,5-Dimethoxy-[N-(2-fluorobenzyl)]phenethylamine). s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine), which does not include substituted cathinones as described in subparagraph 191. 194. Substituted Tryptamines.—Unless specifically excepted or unless listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation containing a 2-(1H-indol-3-yl)ethanamine, for example tryptamine, structure with or without mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups, or by inclusion of the amino nitrogen atom in a cyclic structure, whether or not substituted at the alpha position with an alkyl group, whether or not substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups, including, but not limited to: a. Alpha-Ethyltryptamine. b. Bufotenine. c. DET (Diethyltryptamine). d. DMT (Dimethyltryptamine). e. MET (N-Methyl-N-ethyltryptamine). f. DALT (N,N-Diallyltryptamine). g. EiPT (N-Ethyl-N-isopropyltryptamine). h. MiPT (N-Methyl-N-isopropyltryptamine). i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine). j. 5-Hydroxy-N-methyltryptamine. k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine). l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine). m. Methyltryptamine. n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine). o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine). p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine). q. DiPT (N,N-Diisopropyltryptamine). r. DPT (N,N-Dipropyltryptamine). s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine). t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine). u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine). v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine). w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine). x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine). y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-isopropyltryptamine). z. Methyl-alpha-ethyltryptamine. aa. Bromo-DALT (Bromo-N,N-diallyltryptamine), which does not include tryptamine, psilocyn as described in subparagraph 34., or psilocybin as described in subparagraph 33. 195. Substituted Phenylcyclohexylamines.—Unless specifically excepted or unless listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation containing a phenylcyclohexylamine structure, with or without any substitution on the phenyl ring, any substitution on the cyclohexyl ring, any replacement of the phenyl ring with a thiophenyl or benzothiophenyl ring, with or without substitution on the amine with alkyl, dialkyl, or alkoxy substituents, inclusion of the nitrogen in a cyclic structure, or any combination of the above, including, but not limited to: a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP (Benocyclidine). b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog of phencyclidine). c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine analog of phencyclidine). d. PCPr (Phenylcyclohexylpropylamine). e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene analog of phencyclidine). f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)). g. PCMPA (Phenylcyclohexyl(methoxypropylamine)). h. Methoxetamine. i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine). j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine). k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine). l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine). m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine). n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine). o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine). p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine). q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine). r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine). 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide. 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide. 198. AH-7921, 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]-benzamide. 199. U47700, trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide. 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine, dihydrochloride. (d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including any of its salts, isomers, optical isomers, salts of their isomers, and salts of these optical isomers whenever the existence of such isomers and salts is possible within the specific chemical designation: 1. 1,4-Butanediol. 2. Gamma-butyrolactone (GBL). 3. Gamma-hydroxybutyric acid (GHB). 4. Methaqualone. 5. Mecloqualone. (2) SCHEDULE II.—A substance in Schedule II has a high potential for abuse and has a currently accepted but severely restricted medical use in treatment in the United States, and abuse of the substance may lead to severe psychological or physical dependence. The following substances are controlled in Schedule II: (a) Unless specifically excepted or unless listed in another schedule, any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis: 1. Opium and any salt, compound, derivative, or preparation of opium, except nalmefene or isoquinoline alkaloids of opium, including, but not limited to the following: a. Raw opium. b. Opium extracts. c. Opium fluid extracts. d. Powdered opium. e. Granulated opium. f. Tincture of opium. g. Codeine. h. Dihydroetorphine. i. Ethylmorphine. j. Etorphine hydrochloride. k. Hydrocodone and hydrocodone combination products. l. Hydromorphone. m. Levo-alphacetylmethadol (also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM). n. Metopon (methyldihydromorphinone). o. Morphine. p. Oripavine. q. Oxycodone. r. Oxymorphone. s. Thebaine. 2. Any salt, compound, derivative, or preparation of a substance which is chemically equivalent to or identical with any of the substances referred to in subparagraph 1., except that these substances shall not include the isoquinoline alkaloids of opium. 3. Any part of the plant of the species Papaver somniferum, L. 4. Cocaine or ecgonine, including any of their stereoisomers, and any salt, compound, derivative, or preparation of cocaine or ecgonine, except that these substances shall not include ioflupane I 123. (b) Unless specifically excepted or unless listed in another schedule, any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: 1. Alfentanil. 2. Alphaprodine. 3. Anileridine. 4. Bezitramide. 5. Bulk propoxyphene (nondosage forms). 6. Carfentanil. 7. Dihydrocodeine. 8. Diphenoxylate. 9. Fentanyl. 10. Isomethadone. 11. Levomethorphan. 12. Levorphanol. 13. Metazocine. 14. Methadone. 15. Methadone-Intermediate,4-cyano-2- dimethylamino-4,4-diphenylbutane. 16. Moramide-Intermediate,2-methyl- 3-morpholoino-1,1-diphenylpropane-carboxylic acid. 17. Nabilone. 18. Pethidine (meperidine). 19. Pethidine-Intermediate-A,4-cyano-1- methyl-4-phenylpiperidine. 20. Pethidine-Intermediate-B,ethyl-4- phenylpiperidine-4-carboxylate. 21. Pethidine-Intermediate-C,1-methyl-4- phenylpiperidine-4-carboxylic acid. 22. Phenazocine. 23. Phencyclidine. 24. 1-Phenylcyclohexylamine. 25. Piminodine. 26. 1-Piperidinocyclohexanecarbonitrile. 27. Racemethorphan. 28. Racemorphan. 29. Remifentanil. 30. Sufentanil. 31. Tapentadol. 32. Thiafentanil. (c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including their salts, isomers, optical isomers, salts of their isomers, and salts of their optical isomers: 1. Amobarbital. 2. Amphetamine. 3. Glutethimide. 4. Lisdexamfetamine. 5. Methamphetamine. 6. Methylphenidate. 7. Pentobarbital. 8. Phenmetrazine. 9. Phenylacetone. 10. Secobarbital. (d) Dronabinol (synthetic THC) in oral solution in a drug product approved by the United States Food and Drug Administration. (3) SCHEDULE III.—A substance in Schedule III has a potential for abuse less than the substances contained in Schedules I and II and has a currently accepted medical use in treatment in the United States, and abuse of the substance may lead to moderate or low physical dependence or high psychological dependence or, in the case of anabolic steroids, may lead to physical damage. The following substances are controlled in Schedule III: (a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant or stimulant effect on the nervous system: 1. Any substance which contains any quantity of a derivative of barbituric acid, including thiobarbituric acid, or any salt of a derivative of barbituric acid or thiobarbituric acid, including, but not limited to, butabarbital and butalbital. 2. Benzphetamine. 3. Buprenorphine. 4. Chlorhexadol. 5. Chlorphentermine. 6. Clortermine. 7. Embutramide. 8. Lysergic acid. 9. Lysergic acid amide. 10. Methyprylon. 11. Perampanel. 12. Phendimetrazine. 13. Sulfondiethylmethane. 14. Sulfonethylmethane. 15. Sulfonmethane. 16. Tiletamine and zolazepam or any salt thereof. (b) Nalorphine. (c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following controlled substances or any salts thereof: 1. Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium. 2. Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with recognized therapeutic amounts of one or more active ingredients which are not controlled substances. 3. Not more than 300 milligrams of hydrocodone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium. 4. Not more than 300 milligrams of hydrocodone per 100 milliliters or not more than 15 milligrams per dosage unit, with recognized therapeutic amounts of one or more active ingredients that are not controlled substances. 5. Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with recognized therapeutic amounts of one or more active ingredients which are not controlled substances. 6. Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. 7. Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with recognized therapeutic amounts of one or more active ingredients which are not controlled substances. For purposes of charging a person with a violation of s. 893.135 involving any controlled substance described in subparagraph 3. or subparagraph 4., the controlled substance is a Schedule III controlled substance pursuant to this paragraph but the weight of the controlled substance per milliliters or per dosage unit is not relevant to the charging of a violation of s. 893.135. The weight of the controlled substance shall be determined pursuant to s. 893.135(6). (d) Anabolic steroids. 1. The term “anabolic steroid” means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, and corticosteroids, that promotes muscle growth and includes: a. Androsterone. b. Androsterone acetate. c. Boldenone. d. Boldenone acetate. e. Boldenone benzoate. f. Boldenone undecylenate. g. Chlorotestosterone (Clostebol). h. Dehydrochlormethyltestosterone. i. Dihydrotestosterone (Stanolone). j. Drostanolone. k. Ethylestrenol. l. Fluoxymesterone. m. Formebulone (Formebolone). n. Mesterolone. o. Methandrostenolone (Methandienone). p. Methandranone. q. Methandriol. r. Methenolone. s. Methyltestosterone. t. Mibolerone. u. Nortestosterone (Nandrolone). v. Norethandrolone. w. Nortestosterone decanoate. x. Nortestosterone phenylpropionate. y. Nortestosterone propionate. z. Oxandrolone. aa. Oxymesterone. bb. Oxymetholone. cc. Stanozolol. dd. Testolactone. ee. Testosterone. ff. Testosterone acetate. gg. Testosterone benzoate. hh. Testosterone cypionate. ii. Testosterone decanoate. jj. Testosterone enanthate. kk. Testosterone isocaproate. ll. Testosterone oleate. mm. Testosterone phenylpropionate. nn. Testosterone propionate. oo. Testosterone undecanoate. pp. Trenbolone. qq. Trenbolone acetate. rr. Any salt, ester, or isomer of a drug or substance described or listed in this subparagraph if that salt, ester, or isomer promotes muscle growth. 2. The term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the United States Secretary of Health and Human Services for such administration. However, any person who prescribes, dispenses, or distributes such a steroid for human use is considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph. (e) Ketamine, including any isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. (f) Dronabinol (synthetic THC) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration. (g) Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under s. 505 of the Federal Food, Drug, and Cosmetic Act. (4) SCHEDULE IV.— (a) A substance in Schedule IV has a low potential for abuse relative to the substances in Schedule III and has a currently accepted medical use in treatment in the United States, and abuse of the substance may lead to limited physical or psychological dependence relative to the substances in Schedule III. (b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, are controlled in Schedule IV: 1. Alfaxalone. 2. Alprazolam. 3. Barbital. 4. Bromazepam. 5. Butorphanol tartrate. 6. Camazepam. 7. Carisoprodol. 8. Cathine. 9. Chloral betaine. 10. Chloral hydrate. 11. Chlordiazepoxide. 12. Clobazam. 13. Clonazepam. 14. Clorazepate. 15. Clotiazepam. 16. Cloxazolam. 17. Dexfenfluramine. 18. Delorazepam. 19. Dichloralphenazone. 20. Diazepam. 21. Diethylpropion. 22. Eluxadoline. 23. Estazolam. 24. Eszopiclone. 25. Ethchlorvynol. 26. Ethinamate. 27. Ethyl loflazepate. 28. Fencamfamin. 1 29. Fenfluramine. 30. Fenproporex. 31. Fludiazepam. 32. Flurazepam. 33. Fospropofol. 34. Halazepam. 35. Haloxazolam. 36. Ketazolam. 37. Loprazolam. 38. Lorazepam. 39. Lorcaserin. 40. Lormetazepam. 41. Mazindol. 42. Mebutamate. 43. Medazepam. 44. Mefenorex. 45. Meprobamate. 46. Methohexital. 47. Methylphenobarbital. 48. Midazolam. 49. Modafinil. 50. Nimetazepam. 51. Nitrazepam. 52. Nordiazepam. 53. Oxazepam. 54. Oxazolam. 55. Paraldehyde. 56. Pemoline. 57. Pentazocine. 58. Petrichloral. 59. Phenobarbital. 60. Phentermine. 61. Pinazepam. 62. Pipradrol. 63. Prazepam. 64. Propoxyphene (dosage forms). 65. Propylhexedrine, excluding any patent or proprietary preparation containing propylhexedrine, unless otherwise provided by federal law. 66. Quazepam. 67. Sibutramine. 68. SPA[(-)-1 dimethylamino-1, 2 diphenylethane]. 69. Suvorexant. 70. Temazepam. 71. Tetrazepam. 72. Tramadol. 73. Triazolam. 74. Zaleplon. 75. Zolpidem. 76. Zopiclone. 77. Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit. (5) SCHEDULE V.—A substance, compound, mixture, or preparation of a substance in Schedule V has a low potential for abuse relative to the substances in Schedule IV and has a currently accepted medical use in treatment in the United States, and abuse of such compound, mixture, or preparation may lead to limited physical or psychological dependence relative to the substances in Schedule IV. (a) Substances controlled in Schedule V include any compound, mixture, or preparation containing any of the following limited quantities of controlled substances, which must include one or more active medicinal ingredients that are not controlled substances in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the controlled substance alone: 1. Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams. 2. Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams. 3. Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams. 4. Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit. 5. Not more than 100 milligrams of opium per 100 milliliters or per 100 grams. 6. Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit. (b) Unless a specific exception exists or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances is controlled in Schedule V: 1. Brivaracetam. 2. Ezogabine. 3. Lacosamide. 4. Pregabalin. (c) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: Pyrovalerone. History.—s. 3, ch. 73-331; s. 247, ch. 77-104; s. 1, ch. 77-174; ss. 1, 2, ch. 78-195; s. 2, ch. 79-325; s. 1, ch. 80-353; s. 1, ch. 82-16; s. 1, ch. 84-89; s. 2, ch. 85-242; s. 1, ch. 86-147; s. 2, ch. 87-243; s. 1, ch. 87-299; s. 1, ch. 88-59; s. 3, ch. 89-281; s. 54, ch. 92-69; s. 1, ch. 93-92; s. 4, ch. 95-415; s. 1, ch. 96-360; ss. 1, 5, ch. 97-1; s. 96, ch. 97-264; s. 1, ch. 99-186; s. 2, ch. 2000-320; s. 1, ch. 2001-55; s. 5, ch. 2001-57; s. 1, ch. 2002-78; s. 2, ch. 2003-10; s. 1, ch. 2008-88; s. 2, ch. 2011-73; s. 1, ch. 2011-90; s. 1, ch. 2012-23; s. 1, ch. 2013-29; s. 1, ch. 2014-159; s. 1, ch. 2015-34; s. 2, ch. 2016-105; s. 4, ch. 2017-107; s. 1, ch. 2017-110; s. 8, ch. 2018-13; s. 2, ch. 2019-166; s. 1, ch. 2021-154; s. 1, ch. 2023-221; s. 1, ch. 2024-20. 1 Note.—Section 5, ch. 97-1, repealed paragraph (4)(w) effective upon the removal of fenfluramine from the schedules of controlled substances in 21 C.F.R. s. 1308. Paragraph (4)(w) was redesignated as subparagraph (4)(b)29. by s. 8, ch. 2018-3. The Drug Enforcement Administration, United States Department of Justice, in FR Doc. 2022-27400, filed December 22, 2022, issued a final rule removing fenfluramine from the schedules of the Controlled Substances Act, effective December 23, 2022. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d1ae87c67e1',t:'MTc3MDg4MjU1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-03/"
    },
    {
      "id": "section-8930301death",
      "number": "893.0301",
      "heading": "Death resulting from apparent drug overdose; reporting requirements.",
      "text": "resulting from apparent drug overdose; reporting requirements.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-893031industrial",
      "number": "893.031",
      "heading": "Industrial exceptions to controlled substance scheduling.",
      "text": "893.031 Industrial exceptions to controlled substance scheduling.— (1) For the purpose of this section, the following meanings of terms shall apply: (a) “Manufacture” means any process or operation necessary for manufacturing a product. (b) “Distribution” means any process or operation necessary for distributing a product, including, but not limited to, wholesaling, delivery or transport, and storage. (c) “Manufacturer of 1,4-Butanediol” means a person who is involved in the manufacture of 1,4-Butanediol for use in the manufacture of an industrial product and who provides that manufactured 1,4-Butanediol to a distributor of 1,4-Butanediol or a manufacturer of an industrial product. (d) “Distributor of 1,4-Butanediol” means a person who is involved in the distribution of 1,4-Butanediol. (e) “Manufacturer of gamma-butyrolactone (GBL)” means a person who: 1. Is involved in the manufacture of gamma-butyrolactone (GBL) for use in the manufacture of an industrial product and who provides that manufactured gamma-butyrolactone (GBL) to a distributor of gamma-butyrolactone (GBL) or a manufacturer of an industrial product; and 2. Is in compliance with any requirements to register with the United States Drug Enforcement Administration as a List I Chemical registrant. (f) “Distributor of gamma-butyrolactone (GBL)” means a person who: 1. Is involved in the distribution of gamma-butyrolactone (GBL); and 2. Is in compliance with any requirements to register with the United States Drug Enforcement Administration as a List I Chemical registrant. (g) “Manufacturer of an industrial product” means a person who is involved in the manufacture of an industrial product in which that person acquires: 1. 1,4-Butanediol from a manufacturer of 1,4-Butanediol or a distributor of 1,4-Butanediol and who possesses that substance for use in the manufacture of an industrial product; or 2. Gamma-butyrolactone (GBL) from a manufacturer of gamma-butyrolactone (GBL) or a distributor of gamma-butyrolactone (GBL) and who possesses that substance for use in the manufacture of an industrial product. (h) “Distributor of an industrial product” means a person who is involved in the distribution of an industrial product. (i) “Industrial product” means a nondrug, noncontrolled finished product that is not for human consumption. (j) “Finished product” means a product: 1. That does not contain either 1,4-Butanediol or gamma-butyrolactone (GBL); or 2. From which neither 1,4-Butanediol nor gamma-butyrolactone (GBL) can be readily extracted or readily synthesized and which is not sold for human consumption. (2) 1,4-Butanediol is excepted from scheduling pursuant to s. 893.03(1)(d)1. when that substance is in the possession of: (a) A manufacturer of 1,4-Butanediol or a distributor of 1,4-Butanediol; (b) A manufacturer of an industrial product or a distributor of an industrial product; or (c) A person possessing a finished product. (3) Gamma-butyrolactone (GBL) is excepted from scheduling pursuant to s. 893.03(1)(d)2. when that substance is in the possession of: (a) A manufacturer of gamma-butyrolactone (GBL) or a distributor of gamma-butyrolactone (GBL); (b) A manufacturer of an industrial product or a distributor of an industrial product; or (c) A person possessing a finished product. (4) This section does not apply to: (a) A manufacturer of 1,4-Butanediol or a distributor of 1,4-Butanediol who sells, delivers, or otherwise distributes that substance to a person who is not a distributor of 1,4-Butanediol or a manufacturer of an industrial product; (b) A manufacturer of gamma-butyrolactone (GBL) or a distributor of gamma-butyrolactone (GBL) who sells, delivers, or otherwise distributes that substance to a person who is not a distributor of gamma-butyrolactone (GBL) or a manufacturer of an industrial product; (c) A person who possesses 1,4-Butanediol but who is not a manufacturer of 1,4-Butanediol, a distributor of 1,4-Butanediol, a manufacturer of an industrial product, a distributor of an industrial product, or a person possessing a finished product as described in paragraph (2)(c) or paragraph (3)(c); (d) A person who possesses gamma-butyrolactone (GBL) but who is not a manufacturer of gamma-butyrolactone (GBL), a distributor of gamma-butyrolactone (GBL), a manufacturer of an industrial product, a distributor of an industrial product, or a person possessing a finished product as described in paragraph (2)(c) or paragraph (3)(c); (e) A person who extracts or synthesizes either 1,4-Butanediol or gamma-butyrolactone (GBL) from a finished product as described in subparagraph(1)(j)2. or a person who extracts or synthesizes 1,4-Butanediol or gamma-butyrolactone (GBL) from any product or material, unless such extraction or synthesis is authorized by law; or (f) A person whose possession of either 1,4-Butanediol or gamma-butyrolactone (GBL) is not in compliance with the requirements of this section or whose possession of either of those substances is not specifically authorized by law. History.—s. 1, ch. 2003-10. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d1d3ce62631',t:'MTc3MDg4MjU1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-031/"
    },
    {
      "id": "section-893033listed",
      "number": "893.033",
      "heading": "Listed chemicals.",
      "text": "893.033 Listed chemicals.—The chemicals listed in this section are included by whatever official, common, usual, chemical, or trade name designated. (1) PRECURSOR CHEMICALS.—The term “listed precursor chemical” means a chemical that may be used in manufacturing a controlled substance in violation of this chapter and is critical to the creation of the controlled substance, and such term includes any salt, optical isomer, or salt of an optical isomer, whenever the existence of such salt, optical isomer, or salt of optical isomer is possible within the specific chemical designation. The following are “listed precursor chemicals”: (a) Anthranilic acid. (b) Benzaldehyde. (c) Benzyl cyanide. (d) Chloroephedrine. (e) Chloropseudoephedrine. (f) Ephedrine. (g) Ergonovine. (h) Ergotamine. (i) Ergocristine. (j) Ethylamine. (k) Iodine tincture above 2.2 percent. (l) Isosafrole. (m) Methylamine. (n) 3, 4-Methylenedioxyphenyl-2-propanone. (o) N-Acetylanthranilic acid. (p) N-Ethylephedrine. (q) N-Ethylpseudoephedrine. (r) N-Methylephedrine. (s) N-Methylpseudoephedrine. (t) ANPP (4-Anilino-N-phenethyl-4-piperidine). (u) NPP (N-Phenethyl-4-piperidone). (v) Nitroethane. (w) Norpseudoephedrine. (x) Phenylacetic acid. (y) Phenylpropanolamine. (z) Piperidine. (aa) Piperonal. (bb) Propionic anhydride. (cc) Pseudoephedrine. (dd) Safrole. (2) ESSENTIAL CHEMICALS.—The term “listed essential chemical” means a chemical that may be used as a solvent, reagent, or catalyst in manufacturing a controlled substance in violation of this chapter. The following are “listed essential chemicals”: (a) Acetic anhydride. (b) Acetone. (c) Ammonium salts, including, but not limited to, nitrate, sulfate, phosphate, or chloride. (d) Anhydrous ammonia. (e) Benzoquinone. (f) Benzyl chloride. (g) 2-Butanone. (h) Ethyl ether. (i) Formic acid. (j) Hydrochloric acid. (k) Hydriodic acid. (l) Iodine. (m) Lithium. (n) Organic solvents, including, but not limited to, Coleman Fuel, camping fuel, ether, toluene, or lighter fluid. (o) Organic cosolvents, including, but not limited to, glycerol, propylene glycol, or polyethylene glycol. (p) Potassium dichromate. (q) Potassium permanganate. (r) Sodium. (s) Sodium dichromate. (t) Sodium borohydride. (u) Sodium cyanoborohydride. (v) Sodium hydroxide. (w) Sulfuric acid. History.—s. 2, ch. 91-279; s. 6, ch. 2001-57; s. 2, ch. 2003-15; s. 1, ch. 2005-128; s. 3, ch. 2016-105. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d1f9e5bb883',t:'MTc3MDg4MjU2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-033/"
    },
    {
      "id": "section-893035control",
      "number": "893.035",
      "heading": "Control of new substances; findings of fact; delegation of authority to Attorney General to control substances by rule.",
      "text": "of new substances; findings of fact; delegation of authority to Attorney General to control substances by rule.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-8930355control",
      "number": "893.0355",
      "heading": "Control of scheduled substances; delegation of authority to Attorney General to reschedule substance, or delete substance, by rule.",
      "text": "of scheduled substances; delegation of authority to Attorney General to reschedule substance, or delete substance, by rule.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-8930356control",
      "number": "893.0356",
      "heading": "Control of new substances; findings of fact; “controlled substance analog” defined.",
      "text": "of new substances; findings of fact; “controlled substance analog” defined.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-89304pharmacist",
      "number": "893.04",
      "heading": "Pharmacist and practitioner.",
      "text": "893.04 Pharmacist and practitioner.— (1) A pharmacist, in good faith and in the course of professional practice only, may dispense controlled substances upon a written, oral, or electronic prescription of a practitioner, under the following conditions: (a) Oral prescriptions must be promptly reduced to writing by the pharmacist or recorded electronically if permitted by federal law. (b) The written prescription must be dated and signed by the prescribing practitioner on the day when issued. (c) There shall appear on the face of the prescription or written record thereof for the controlled substance the following information: 1. The full name and address of the person for whom, or the owner of the animal for which, the controlled substance is dispensed. 2. The full name and address of the prescribing practitioner and the practitioner’s federal controlled substance registry number shall be printed thereon. 3. If the prescription is for an animal, the species of animal for which the controlled substance is prescribed. 4. The name of the controlled substance prescribed and the strength, quantity, and directions for use thereof. 5. The number of the prescription, as recorded in the prescription files of the pharmacy in which it is filled. 6. The initials of the pharmacist filling the prescription and the date filled. (d) The prescription shall be retained on file by the proprietor of the pharmacy in which it is filled for a period of 2 years. (e) Affixed to the original container in which a controlled substance is delivered upon a prescription or authorized refill thereof, as hereinafter provided, there shall be a label bearing the following information: 1. The name and address of the pharmacy from which such controlled substance was dispensed. 2. The date on which the prescription for such controlled substance was filled. 3. The number of such prescription, as recorded in the prescription files of the pharmacy in which it is filled. 4. The name of the prescribing practitioner. 5. The name of the patient for whom, or of the owner and species of the animal for which, the controlled substance is prescribed. 6. The directions for the use of the controlled substance prescribed in the prescription. 7. A clear, concise warning that it is a crime to transfer the controlled substance to any person other than the patient for whom prescribed. (f) A prescription for a controlled substance listed in Schedule II may be dispensed only upon a written or electronic prescription of a practitioner, except that in an emergency situation, as defined by regulation of the Department of Health, such controlled substance may be dispensed upon oral prescription but is limited to a 72-hour supply. A prescription for a controlled substance listed in Schedule II may not be refilled. (g) A prescription for a controlled substance listed in Schedule III, Schedule IV, or Schedule V may not be filled or refilled more than five times within a period of 6 months after the date on which the prescription was written unless the prescription is renewed by a practitioner. (2)(a) A pharmacist may not dispense a controlled substance listed in Schedule II, Schedule III, or Schedule IV to any patient or patient’s agent without first determining, in the exercise of her or his professional judgment, that the prescription is valid. The pharmacist may dispense the controlled substance, in the exercise of her or his professional judgment, when the pharmacist or pharmacist’s agent has obtained satisfactory patient information from the patient or the patient’s agent. (b) Any pharmacist who dispenses by mail a controlled substance listed in Schedule II, Schedule III, or Schedule IV is exempt from the requirement to obtain suitable identification for the prescription dispensed by mail if the pharmacist has obtained the patient’s identification through the patient’s prescription benefit plan. (c) Any controlled substance listed in Schedule III or Schedule IV may be dispensed by a pharmacist upon an oral prescription if, before filling the prescription, the pharmacist reduces it to writing or records the prescription electronically if permitted by federal law. Such prescriptions must contain the date of the oral authorization. (d) Each prescription written by a practitioner in this state for a controlled substance listed in Schedule II, Schedule III, or Schedule IV must include a written and a numerical notation of the quantity of the controlled substance prescribed and a notation of the date in numerical, month/day/year format, or with the abbreviated month written out, or the month written out in whole. A pharmacist may, upon verification by the prescriber, document any information required by this paragraph. If the prescriber is not available to verify a prescription, the pharmacist may dispense the controlled substance, but may insist that the person to whom the controlled substance is dispensed provide valid photographic identification. If a prescription includes a numerical notation of the quantity of the controlled substance or date, but does not include the quantity or date written out in textual format, the pharmacist may dispense the controlled substance without verification by the prescriber of the quantity or date if the pharmacy previously dispensed another prescription for the person to whom the prescription was written. (e) A pharmacist may not dispense more than a 30-day supply of a controlled substance listed in Schedule III upon an oral prescription issued in this state. (f) A pharmacist may not knowingly dispense a prescription that has been forged for a controlled substance listed in Schedule II, Schedule III, or Schedule IV. (3) Notwithstanding subsection (1), a pharmacist may dispense a one-time emergency refill of up to a 72-hour supply of the prescribed medication for any medicinal drug other than a medicinal drug listed in Schedule II, or emergency refill of insulin and insulin-related supplies or equipment to treat diabetes mellitus, not to exceed 3 nonconsecutive times per calendar year, in compliance with s. 465.0275. (4) The legal owner of any stock of controlled substances in a pharmacy, upon discontinuance of dealing in controlled substances, may sell said stock to a manufacturer, wholesaler, or pharmacy. Such controlled substances may be sold only upon an order form, when such an order form is required for sale by the drug abuse laws of the United States or this state, or regulations pursuant thereto. History.—s. 4, ch. 73-331; s. 2, ch. 75-18; s. 12, ch. 79-12; s. 2, ch. 90-2; s. 1436, ch. 97-102; s. 301, ch. 99-8; s. 2, ch. 2007-156; s. 5, ch. 2009-202; s. 5, ch. 2014-113; s. 6, ch. 2016-145; s. 35, ch. 2016-230; s. 9, ch. 2018-13; s. 2, ch. 2024-79. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d21fabb31e9',t:'MTc3MDg4MjU2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-04/"
    },
    {
      "id": "section-89305practitioners",
      "number": "893.05",
      "heading": "Practitioners and persons administering controlled substances in their absence.",
      "text": "and persons administering controlled substances in their absence.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-893055prescription",
      "number": "893.055",
      "heading": "Prescription drug monitoring program.",
      "text": "893.055 Prescription drug monitoring program.— (1) As used in this section, the term: (a) “Active investigation” means an investigation that is being conducted with a reasonable, good faith belief that it could lead to the filing of administrative, civil, or criminal proceedings, or that is ongoing and continuing and for which there is a reasonable, good faith anticipation of securing an arrest or prosecution in the foreseeable future. (b) “Administration” means the obtaining and giving of a single dose of a controlled substance by a legally authorized person to a patient for her or his consumption. (c) “Controlled substance” means a controlled substance listed in Schedule II, Schedule III, Schedule IV, or Schedule V of s. 893.03 or 21 U.S.C. s. 812. (d) “Dispense” means the transfer of possession of one or more doses of a controlled substance by a dispenser to the ultimate consumer or to his or her agent. (e) “Dispenser” means a dispensing health care practitioner, pharmacy, or pharmacist licensed to dispense controlled substances in or into this state. (f) “Electronic health recordkeeping system” means an electronic or computer-based information system used by health care practitioners or providers to create, collect, store, manipulate, exchange, or make available personal health information for the delivery of patient care. (g) “Health care practitioner” or “practitioner” means any practitioner licensed under chapter 458, chapter 459, chapter 461, chapter 463, chapter 464, chapter 465, or chapter 466. (h) “Health care regulatory board” has the same meaning as in s. 456.001(1). (i) “Law enforcement agency” means the Department of Law Enforcement, a sheriff’s office in this state, a police department in this state, or a law enforcement agency of the Federal Government which enforces the laws of this state or the United States relating to controlled substances and whose agents and officers are empowered by law to conduct criminal investigations and make arrests. (j) “Pharmacy” includes a community pharmacy, an institutional pharmacy, a nuclear pharmacy, a special pharmacy, or an Internet pharmacy that is licensed by the department under chapter 465 and that dispenses or delivers controlled substances to an individual or address in this state. (k) “Prescriber” means a prescribing physician, prescribing practitioner, or other prescribing health care practitioner authorized by the laws of this state to order controlled substances. (l) “Program manager” means an employee of or a person contracted by the department who is designated to ensure the integrity of the prescription drug monitoring program in accordance with the requirements established in this section. (2)(a) The department shall maintain an electronic system to collect and store controlled substance dispensing information and shall release the information as authorized in this section and s. 893.0551. The electronic system must: 1. Not infringe upon the legitimate prescribing or dispensing of a controlled substance by a prescriber or dispenser acting in good faith and in the course of professional practice. 2. Be consistent with standards of the American Society for Automation in Pharmacy. 3. Comply with the Health Insurance Portability and Accountability Act as it pertains to protected health information, electronic protected health information, and all other relevant state and federal privacy and security laws and regulations. 4. Purge or cause to be purged information in the database that is more than 4 years old. (b) The department may collaborate with professional health care regulatory boards, appropriate organizations, and other state agencies to identify indicators of controlled substance abuse. (3)(a) For each controlled substance dispensed to a patient in this state, the following information must be reported by the dispenser to the system as soon thereafter as possible but no later than the close of the next business day after the day the controlled substance is dispensed unless an extension or exemption is approved by the department: 1. The name of the prescribing practitioner, the practitioner’s federal Drug Enforcement Administration registration number, the practitioner’s National Provider Identification or other appropriate identifier, and the date of the prescription. 2. The date the prescription was filled and the method of payment, such as cash by an individual, insurance coverage through a third party, or Medicaid payment. This paragraph does not authorize the department to include individual credit card numbers or other account numbers in the system. 3. The full name, address, telephone number, and date of birth of the person for whom the prescription was written. 4. The name, national drug code, quantity, and strength of the controlled substance dispensed. 5. The full name, federal Drug Enforcement Administration registration number, State of Florida Department of Health issued pharmacy permit number, and address of the pharmacy or other location from which the controlled substance was dispensed. If the controlled substance was dispensed by a practitioner other than a pharmacist, the practitioner’s full name, address, federal Drug Enforcement Administration registration number, State of Florida Department of Health issued license number, and National Provider Identification. 6. Whether the drug was dispensed as an initial prescription or a refill, and the number of refills ordered. 7. The name of the individual picking up the controlled substance prescription and type and issuer of the identification provided. 8. Other appropriate identifying information as determined by department rule. (b) The following acts of administration or dispensing are exempt from the reporting requirements of this subsection: 1. All acts of administration of a controlled substance. 2. The dispensing of a controlled substance in the health care system of the Department of Corrections. 3. The dispensing of a controlled substance to a person under the age of 16. (4) The following persons must be provided direct access to information in the system: (a) A prescriber or dispenser or his or her designee. (b) An employee of the United States Department of Veterans Affairs, the United States Department of Defense, or the Indian Health Service who provides health care services pursuant to such employment and who has the authority to prescribe or dispense controlled substances shall have access to the information in the program’s system upon verification of employment. (c) The program manager or designated program and support staff to administer the system. 1. In order to calculate performance measures pursuant to subsection (14), the program manager or program and support staff members who have been directed by the program manager to calculate performance measures may have direct access to information that contains no identifying information of any patient, physician, health care practitioner, prescriber, or dispenser. 2. The program manager or designated program and support staff must provide the department, upon request, data that does not contain patient, physician, health care practitioner, prescriber, or dispenser identifying information for public health care and safety initiatives purposes. 3. The program manager, upon determining a pattern consistent with the department’s rules established under subsection (16), may provide relevant information to the prescriber and dispenser. 4. The program manager, upon determining a pattern consistent with the rules established under subsection (16) and having cause to believe a violation of s. 893.13(7)(a)8., (8)(a), or (8)(b) has occurred, may provide relevant information to the applicable law enforcement agency. The program manager and designated program and support staff must complete a level II background screening. (5) The following entities may not directly access information in the system, but may request information from the program manager or designated program and support staff: (a) The department and its health care regulatory boards, as appropriate, for investigations involving licensees authorized to prescribe or dispense controlled substances. (b) The Attorney General for Medicaid fraud cases involving prescribed controlled substances. (c) A law enforcement agency during active investigations of potential criminal activity, fraud, or theft regarding prescribed controlled substances. (d) A medical examiner when conducting an authorized investigation under s. 406.11, to determine the cause of death of an individual. (e) An impaired practitioner consultant who is retained by the department under s. 456.076 to review the system information of an impaired practitioner program participant or a referral who has agreed to be evaluated or monitored through the program and who has separately agreed in writing to the consultant’s access to and review of such information. (f) A patient or the legal guardian or designated health care surrogate of an incapacitated patient who submits a written and notarized request that includes the patient’s full name, address, phone number, date of birth, and a copy of a government-issued photo identification. (6) The department may enter into one or more reciprocal agreements or contracts to share prescription drug monitoring information with other states, districts, territories, the United States Department of Veterans Affairs, the United States Department of Defense, or the Indian Health Service if the prescription drug monitoring programs of such other states, districts, territories, the United States Department of Veterans Affairs, the United States Department of Defense, or the Indian Health Service are compatible with the Florida program. (a) In determining compatibility, the department shall consider: 1. The safeguards for privacy of patient records and the success of the program in protecting patient privacy. 2. The persons authorized to view the data collected by the program. Comparable entities and licensed health care practitioners in other states, districts, or territories of the United States; law enforcement agencies; the Attorney General’s Medicaid Fraud Control Unit; medical regulatory boards; the United States Department of Veterans Affairs; the United States Department of Defense; the Indian Health Service; and, as needed, management staff who have similar duties as management staff who work with the prescription drug monitoring program as authorized in s. 893.0551 are authorized access upon approval by the department. 3. The schedules of the controlled substances that are monitored by the program. 4. The data reported to or included in the program’s system. 5. Any implementing criteria deemed essential for a thorough comparison. 6. The costs and benefits to the state of sharing prescription information. (b) The department shall assess the prescription drug monitoring program’s continued compatibility every 4 years with programs from other states, districts, territories, the United States Department of Veterans Affairs, the United States Department of Defense, or the Indian Health Service. (c) Any agreements or contracts for sharing of prescription drug monitoring information between the department and other states, districts, territories, the United States Department of Veterans Affairs, the United States Department of Defense, or the Indian Health Service shall contain the same restrictions and requirements as this section or s. 893.0551, and the information must be provided according to the department’s determination of compatibility. (7) The department may enter into agreements or contracts to establish secure connections between the system and a prescribing or dispensing health care practitioner’s electronic health recordkeeping system. The electronic health recordkeeping system owner or license holder will be responsible for ensuring that only authorized individuals have access to prescription drug monitoring program information. (8) A prescriber or dispenser or a designee of a prescriber or dispenser must consult the system to review a patient’s controlled substance dispensing history before prescribing or dispensing a controlled substance for a patient age 16 or older. This requirement does not apply when prescribing or dispensing a nonopioid controlled substance listed in Schedule V of s. 893.03 or 21 U.S.C. 812 or prescribing or dispensing a controlled substance to a patient who has been admitted to hospice pursuant to s. 400.6095. For purposes of this subsection, a “nonopioid controlled substance” is a controlled substance that does not contain any amount of a substance listed as an opioid in s. 893.03 or 21 U.S.C. 812. (a) The duty to consult the system does not apply when the system: 1. Is determined by the department to be nonoperational; or 2. Cannot be accessed by the prescriber or dispenser or a designee of the prescriber or dispenser because of a temporary technological or electrical failure. (b) A prescriber or dispenser or designee of a prescriber or dispenser who does not consult the system under this subsection shall document the reason he or she did not consult the system in the patient’s medical record or prescription record and shall not prescribe or dispense greater than a 3-day supply of a controlled substance to the patient. (c) The department shall issue a nondisciplinary citation to any prescriber or dispenser who fails to consult the system as required by this subsection for an initial offense. Each subsequent offense is subject to disciplinary action pursuant to s. 456.073. (9) A person who willfully and knowingly fails to report the dispensing of a controlled substance as required by this section commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083. (10) Information in the prescription drug monitoring program’s system may be released only as provided in this section and s. 893.0551. The content of the system is intended to be informational only. Information in the system is not subject to discovery or introduction into evidence in any civil or administrative action against a prescriber, dispenser, pharmacy, or patient arising out of matters that are the subject of information in the system. The program manager and authorized persons who participate in preparing, reviewing, issuing, or any other activity related to management of the system may not be permitted or required to testify in any such civil or administrative action as to any findings, recommendations, evaluations, opinions, or other actions taken in connection with management of the system. (11) A prescriber or dispenser, or his or her designee, may have access to the information under this section which relates to a patient of that prescriber or dispenser as needed for the purpose of reviewing the patient’s controlled drug prescription history. A prescriber or dispenser acting in good faith is immune from any civil, criminal, or administrative liability that might otherwise be incurred or imposed for receiving or using information from the prescription drug monitoring program. This subsection does not create a private cause of action, and a person may not recover damages against a prescriber or dispenser authorized to access information under this subsection for accessing or failing to access such information. (12)(a) All costs incurred by the department in administering the prescription drug monitoring program shall be funded through federal grants, private funding applied for or received by the state, or state funds appropriated in the General Appropriations Act. The department may not: 1. Commit funds for the monitoring program without ensuring funding is available; or 2. Use funds provided, directly or indirectly, by prescription drug manufacturers to implement the program. (b) The department shall cooperate with the direct-support organization established under subsection (15) in seeking federal grant funds, other nonstate grant funds, gifts, donations, or other private moneys for the department if the costs of doing so are immaterial. Immaterial costs include, but are not limited to, the costs of mailing and personnel assigned to research or apply for a grant. The department may competitively procure and contract pursuant to s. 287.057 for any goods and services required by this section. (13) The department shall conduct or participate in studies to examine the feasibility of enhancing the prescription drug monitoring program for the purposes of public health initiatives and statistical reporting. Such studies shall respect the privacy of the patient, the prescriber, and the dispenser. Such studies may be conducted by the department or a contracted vendor in order to: (a) Improve the quality of health care services and safety by improving prescribing and dispensing practices for controlled substances; (b) Take advantage of advances in technology; (c) Reduce duplicative prescriptions and the overprescribing of controlled substances; and (d) Reduce drug abuse. (14) The department shall annually report on performance measures to the Governor, the President of the Senate, and the Speaker of the House of Representatives by December 1. Performance measures may include, but are not limited to, the following outcomes: (a) Reduction of the rate of inappropriate use of controlled substances through department education and safety efforts. (b) Reduction of the quantity of controlled substances obtained by individuals attempting to engage in fraud and deceit. (c) Increased coordination among partners participating in the prescription drug monitoring program. (d) Involvement of stakeholders in achieving improved patient health care and safety and reduction of controlled substance abuse and controlled substance diversion. (15) The department may establish a direct-support organization to provide assistance, funding, and promotional support for the activities authorized for the prescription drug monitoring program. (a) As used in this subsection, the term “direct-support organization” means an organization that is: 1. A Florida corporation not for profit incorporated under chapter 617, exempted from filing fees, and approved by the Department of State. 2. Organized and operated to conduct programs and activities; raise funds; request and receive grants, gifts, and bequests of money; acquire, receive, hold, and invest, in its own name, securities, funds, objects of value, or other property, either real or personal; and make expenditures or provide funding to or for the direct or indirect benefit of the department in the furtherance of the prescription drug monitoring program. (b) The State Surgeon General shall appoint a board of directors for the direct-support organization. 1. The board of directors shall consist of no fewer than five members who shall serve at the pleasure of the State Surgeon General. 2. The State Surgeon General shall provide guidance to members of the board to ensure that moneys received by the direct-support organization are not received from inappropriate sources. Inappropriate sources include, but are not limited to, donors, grantors, persons, prescription drug manufacturers, or organizations that may monetarily or substantively benefit from the purchase of goods or services by the department in furtherance of the prescription drug monitoring program. (c) The direct-support organization shall operate under written contract with the department. The contract must, at a minimum, provide for: 1. Approval of the articles of incorporation and bylaws of the direct-support organization by the department. 2. Submission of an annual budget for the approval of the department. 3. The reversion, without penalty, to the department’s grants and donations trust fund for the administration of the prescription drug monitoring program of all moneys and property held in trust by the direct-support organization for the benefit of the prescription drug monitoring program if the direct-support organization ceases to exist or if the contract is terminated. 4. The fiscal year of the direct-support organization, which must begin July 1 of each year and end June 30 of the following year. 5. The disclosure of the material provisions of the contract to donors of gifts, contributions, or bequests, including such disclosure on all promotional and fundraising publications, and an explanation to such donors of the distinction between the department and the direct-support organization. 6. The direct-support organization’s collecting, expending, and providing of funds to the department for the development, implementation, and operation of the prescription drug monitoring program as described in this section. The direct-support organization may collect and expend funds to be used for the functions of the direct-support organization’s board of directors, as necessary and approved by the department. In addition, the direct-support organization may collect and provide funding to the department in furtherance of the prescription drug monitoring program by: a. Establishing and administering the prescription drug monitoring program’s electronic system, including hardware and software. b. Conducting studies on the efficiency and effectiveness of the program to include feasibility studies as described in subsection (13). c. Providing funds for future enhancements of the program within the intent of this section. d. Providing user training of the prescription drug monitoring program, including distribution of materials to promote public awareness and education and conducting workshops or other meetings for health care practitioners, pharmacists, and others as appropriate. e. Providing funds for travel expenses. f. Providing funds for administrative costs, including personnel, audits, facilities, and equipment. g. Fulfilling all other requirements necessary to implement and operate the program as outlined in this section. 7. Certification by the department that the direct-support organization is complying with the terms of the contract in a manner consistent with and in furtherance of the goals and purposes of the prescription drug monitoring program and in the best interests of the state. Such certification must be made annually and reported in the official minutes of a meeting of the direct-support organization. (d) The activities of the direct-support organization must be consistent with the goals and mission of the department, as determined by the department, and in the best interests of the state. The direct-support organization must obtain written approval from the department for any activities in support of the prescription drug monitoring program before undertaking those activities. (e) The direct-support organization shall provide for an independent annual financial audit in accordance with s. 215.981. Copies of the audit shall be provided to the department and the Office of Policy and Budget in the Executive Office of the Governor. (f) The direct-support organization may not exercise any power under s. 617.0302(12) or (16). (g) The direct-support organization is not considered a lobbying firm within the meaning of s. 11.045. (h) The department may permit, without charge, appropriate use of administrative services, property, and facilities of the department by the direct-support organization, subject to this section. The use must be directly in keeping with the approved purposes of the direct-support organization and may not be made at times or places that would unreasonably interfere with opportunities for the public to use such facilities for established purposes. Any moneys received from rentals of facilities and properties managed by the department may be held in a separate depository account in the name of the direct-support organization and subject to the provisions of the letter of agreement with the department. The letter of agreement must provide that any funds held in the separate depository account in the name of the direct-support organization must revert to the department if the direct-support organization is no longer approved by the department to operate in the best interests of the state. (i) The department may adopt rules under s. 120.54 to govern the use of administrative services, property, or facilities of the department or office by the direct-support organization. (j) The department may not permit the use of any administrative services, property, or facilities of the state by a direct-support organization if that organization does not provide equal membership and employment opportunities to all persons regardless of race, color, religion, gender, age, or national origin. (k) This subsection is repealed October 1, 2027, unless reviewed and saved from repeal by the Legislature. (16) The department shall adopt rules necessary to implement this section. History.—s. 1, ch. 2009-198; s. 41, ch. 2010-151; s. 12, ch. 2010-211; s. 50, ch. 2011-4; s. 23, ch. 2011-141; s. 86, ch. 2012-5; s. 11, ch. 2013-16; s. 14, ch. 2013-26; s. 21, ch. 2013-154; s. 167, ch. 2014-17; s. 26, ch. 2014-96; s. 32, ch. 2015-222; s. 55, ch. 2016-62; s. 31, ch. 2016-105; s. 1, ch. 2016-177; s. 14, ch. 2017-71; s. 1, ch. 2017-169; s. 1, ch. 2017-191; s. 1, ch. 2017-192; s. 21, ch. 2018-10; s. 10, ch. 2018-13; s. 25, ch. 2018-111; s. 105, ch. 2019-3; s. 1, ch. 2019-70; s. 32, ch. 2019-116; ss. 1, 3, ch. 2019-127; s. 22, ch. 2020-114; s. 25, ch. 2021-131; s. 32, ch. 2022-5; s. 66, ch. 2024-2. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d246fd06dce',t:'MTc3MDg4MjU2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-055/"
    },
    {
      "id": "section-8930551public",
      "number": "893.0551",
      "heading": "Public records exemption for the prescription drug monitoring program.",
      "text": "records exemption for the prescription drug monitoring program.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-89306distribution",
      "number": "893.06",
      "heading": "Distribution of controlled substances; order forms; labeling and packaging requirements.",
      "text": "of controlled substances; order forms; labeling and packaging requirements.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-893065counterfeit-resistant",
      "number": "893.065",
      "heading": "Counterfeit-resistant prescription blanks for controlled substances listed in Schedule II, Schedule III, Schedule IV, or Schedule V.",
      "text": "prescription blanks for controlled substances listed in Schedule II, Schedule III, Schedule IV, or Schedule V.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-89307records",
      "number": "893.07",
      "heading": "Records",
      "text": "893.07 Records.— (1) Every person who engages in the manufacture, compounding, mixing, cultivating, growing, or by any other process producing or preparing, or in the dispensing, importation, or, as a wholesaler, distribution, of controlled substances shall: (a) On January 1, 1974, or as soon thereafter as any person first engages in such activity, and every second year thereafter, make a complete and accurate record of all stocks of controlled substances on hand. The inventory may be prepared on the regular physical inventory date which is nearest to, and does not vary by more than 6 months from, the biennial date that would otherwise apply. As additional substances are designated for control under this chapter, they shall be inventoried as provided for in this subsection. (b) On and after January 1, 1974, maintain, on a current basis, a complete and accurate record of each substance manufactured, received, sold, delivered, or otherwise disposed of by him or her, except that this subsection shall not require the maintenance of a perpetual inventory. Compliance with the provisions of federal law pertaining to the keeping of records of controlled substances shall be deemed a compliance with the requirements of this subsection. (2) The record of controlled substances received shall in every case show: (a) The date of receipt. (b) The name and address of the person from whom received. (c) The kind and quantity of controlled substances received. (3) The record of all controlled substances sold, administered, dispensed, or otherwise disposed of shall show: (a) The date of selling, administering, or dispensing. (b) The correct name and address of the person to whom or for whose use, or the owner and species of animal for which, sold, administered, or dispensed. (c) The kind and quantity of controlled substances sold, administered, or dispensed. (4) Every inventory or record required by this chapter, including prescription records, shall be maintained: (a) Separately from all other records of the registrant, or (b) Alternatively, in the case of Schedule III, IV, or V controlled substances, in such form that information required by this chapter is readily retrievable from the ordinary business records of the registrant. In either case, the records described in this subsection shall be kept and made available for a period of at least 2 years for inspection and copying by law enforcement officers whose duty it is to enforce the laws of this state relating to controlled substances. Law enforcement officers are not required to obtain a subpoena, court order, or search warrant in order to obtain access to or copies of such records. (5) Each person described in subsection (1) shall: (a) Maintain a record which shall contain a detailed list of controlled substances lost, destroyed, or stolen, if any; the kind and quantity of such controlled substances; and the date of the discovering of such loss, destruction, or theft. (b) In the event of the discovery of the theft or significant loss of controlled substances, report such theft or significant loss to the sheriff of that county within 24 hours after discovery. A person who fails to report a theft or significant loss of a substance listed in s. 893.03(3), (4), or (5) within 24 hours after discovery as required in this paragraph commits a misdemeanor of the second degree, punishable as provided in s. 775.082 or s. 775.083. A person who fails to report a theft or significant loss of a substance listed in s. 893.03(2) within 24 hours after discovery as required in this paragraph commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083. History.—s. 7, ch. 73-331; s. 1439, ch. 97-102; s. 25, ch. 2011-141; s. 32, ch. 2016-105; s. 5, ch. 2019-166. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d269843b989',t:'MTc3MDg4MjU2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-07/"
    },
    {
      "id": "section-89308exceptions",
      "number": "893.08",
      "heading": "Exceptions",
      "text": "893.08 Exceptions.— (1) The following may be distributed at retail without a prescription, but only by a registered pharmacist: (a) Any compound, mixture, or preparation described in Schedule V. (b) Any compound, mixture, or preparation containing any depressant or stimulant substance described in s. 893.03(2)(a) or (c) except any amphetamine drug or sympathomimetic amine drug or compound designated as a Schedule II controlled substance pursuant to this chapter; in s. 893.03(3)(a); or in Schedule IV, if: 1. The compound, mixture, or preparation contains one or more active medicinal ingredients not having depressant or stimulant effect on the central nervous system, and 2. Such ingredients are included therein in such combinations, quantity, proportion, or concentration as to vitiate the potential for abuse of the controlled substances which do have a depressant or stimulant effect on the central nervous system. (2) No compound, mixture, or preparation may be dispensed under subsection (1) unless such substance may, under the Federal Food, Drug, and Cosmetic Act, be lawfully sold at retail without a prescription. (3) The exemptions authorized by this section shall be subject to the following conditions: (a) The compounds, mixtures, and preparations referred to in subsection (1) may be dispensed to persons under age 18 only on prescription. A bound volume must be maintained as a record of sale at retail of excepted compounds, mixtures, and preparations, and the pharmacist must require suitable identification from every unknown purchaser. (b) Such compounds, mixtures, and preparations shall be sold by the pharmacist in good faith as a medicine and not for the purpose of evading the provisions of this chapter. The pharmacist may, in his or her discretion, withhold sale to any person whom the pharmacist reasonably believes is attempting to purchase excepted compounds, mixtures, or preparations for the purpose of abuse. (c) The total quantity of controlled substance listed in Schedule V which may be sold to any one purchaser within a given 48-hour period shall not exceed 120 milligrams of codeine, 60 milligrams dihydrocodeine, 30 milligrams of ethyl morphine, or 240 milligrams of opium. (d) Nothing in this section shall be construed to limit the kind and quantity of any controlled substance that may be prescribed, administered, or dispensed to any person, or for the use of any person or animal, when it is prescribed, administered, or dispensed in compliance with the general provisions of this chapter. (4) The dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan) shall not be deemed to be included in any schedule by reason of enactment of this chapter. History.—s. 8, ch. 73-331; s. 1, ch. 77-174; s. 6, ch. 80-354; s. 4, ch. 89-281; s. 2, ch. 93-92; s. 1440, ch. 97-102; s. 105, ch. 97-264; s. 12, ch. 99-186. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d28fae5c294',t:'MTc3MDg4MjU2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-08/"
    },
    {
      "id": "section-89309enforcement",
      "number": "893.09",
      "heading": "Enforcement",
      "text": "893.09 Enforcement.— (1) The Department of Law Enforcement, all state agencies which regulate professions or institutions affected by the provisions of this chapter, and all peace officers of the state shall enforce all provisions of this chapter except those specifically delegated, and shall cooperate with all agencies charged with the enforcement of the laws of the United States, this state, and all other states relating to controlled substances. (2) Any agency authorized to enforce this chapter shall have the right to institute an action in its own name to enjoin the violation of any of the provisions of this chapter. Said action for an injunction shall be in addition to any other action, proceeding, or remedy authorized by law. (3) All law enforcement officers whose duty it is to enforce this chapter shall have authority to administer oaths in connection with their official duties, and any person making a material false statement under oath before such law enforcement officers shall be deemed guilty of perjury and subject to the same punishment as prescribed for perjury. (4) It shall be unlawful and punishable as provided in chapter 843 for any person to interfere with any such law enforcement officer in the performance of the officer’s official duties. It shall also be unlawful for any person falsely to represent himself or herself to be authorized to enforce the drug abuse laws of this state, the United States, or any other state. (5) No civil or criminal liability shall be imposed by virtue of this chapter upon any person whose duty it is to enforce the provisions of this chapter, by reason of his or her being lawfully engaged in the enforcement of any law or municipal ordinance relating to controlled substances. History.—s. 9, ch. 73-331; s. 1, ch. 77-174; s. 30, ch. 79-8; s. 1441, ch. 97-102. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d2b5b6b1670',t:'MTc3MDg4MjU2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-09/"
    },
    {
      "id": "section-89310burden",
      "number": "893.10",
      "heading": "Burden of proof; photograph or video recording of evidence.",
      "text": "of proof; photograph or video recording of evidence.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-893101legislative",
      "number": "893.101",
      "heading": "Legislative findings and intent.",
      "text": "893.101 Legislative findings and intent.— (1) The Legislature finds that the cases of Scott v. State, Slip Opinion No. SC94701 (Fla. 2002) and Chicone v. State, 684 So. 2d 736 (Fla. 1996), holding that the state must prove that the defendant knew of the illicit nature of a controlled substance found in his or her actual or constructive possession, were contrary to legislative intent. (2) The Legislature finds that knowledge of the illicit nature of a controlled substance is not an element of any offense under this chapter. Lack of knowledge of the illicit nature of a controlled substance is an affirmative defense to the offenses of this chapter. (3) In those instances in which a defendant asserts the affirmative defense described in this section, the possession of a controlled substance, whether actual or constructive, shall give rise to a permissive presumption that the possessor knew of the illicit nature of the substance. It is the intent of the Legislature that, in those cases where such an affirmative defense is raised, the jury shall be instructed on the permissive presumption provided in this subsection. History.—s. 1, ch. 2002-258. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d2da8b5c486',t:'MTc3MDg4MjU2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-101/"
    },
    {
      "id": "section-893105testing",
      "number": "893.105",
      "heading": "Testing and destruction of seized substances.",
      "text": "893.105 Testing and destruction of seized substances.— (1) Any controlled substance or listed chemical seized as evidence may be sample tested and weighed by the seizing agency after the seizure. Any such sample and the analysis thereof shall be admissible into evidence in any civil or criminal action for the purpose of proving the nature, composition, and weight of the substance seized. In addition, the seizing agency may photograph or videotape, for use at trial, the controlled substance or listed chemical seized. (2) Controlled substances or listed chemicals that are not retained for sample testing as provided in subsection (1) may be destroyed pursuant to a court order issued in accordance with s. 893.12. History.—s. 1, ch. 82-88; s. 3, ch. 91-279. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d3008c2da83',t:'MTc3MDg4MjU2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-105/"
    },
    {
      "id": "section-89313prohibited",
      "number": "893.13",
      "heading": "Prohibited acts; penalties.",
      "text": "893.13 Prohibited acts; penalties.— (1)(a) Except as authorized by this chapter and chapter 499, a person may not sell, manufacture, or deliver, or possess with intent to sell, manufacture, or deliver, a controlled substance. A person who violates this provision with respect to: 1. A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5. commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 2. A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 3. A controlled substance named or described in s. 893.03(5) commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083. (b) Except as provided in this chapter, a person may not sell or deliver in excess of 10 grams of any substance named or described in s. 893.03(1)(a) or (b), or any combination thereof, or any mixture containing any such substance. A person who violates this paragraph commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (c) Except as authorized by this chapter, a person may not sell, manufacture, or deliver, or possess with intent to sell, manufacture, or deliver, a controlled substance in, on, or within 1,000 feet of the real property comprising a child care facility as defined in s. 402.302 or a public or private elementary, middle, or secondary school between the hours of 6 a.m. and 12 midnight, or at any time in, on, or within 1,000 feet of real property comprising a state, county, or municipal park, a community center, or a publicly owned recreational facility. As used in this paragraph, the term “community center” means a facility operated by a nonprofit community-based organization for the provision of recreational, social, or educational services to the public. A person who violates this paragraph with respect to: 1. A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5. commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. The defendant must be sentenced to a minimum term of imprisonment of 3 calendar years unless the offense was committed within 1,000 feet of the real property comprising a child care facility as defined in s. 402.302. 2. A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 3. Any other controlled substance, except as lawfully sold, manufactured, or delivered, must be sentenced to pay a $500 fine and to serve 100 hours of public service in addition to any other penalty prescribed by law. This paragraph does not apply to a child care facility unless the owner or operator of the facility posts a sign that is not less than 2 square feet in size with a word legend identifying the facility as a licensed child care facility and that is posted on the property of the child care facility in a conspicuous place where the sign is reasonably visible to the public. (d) Except as authorized by this chapter, a person may not sell, manufacture, or deliver, or possess with intent to sell, manufacture, or deliver, a controlled substance in, on, or within 1,000 feet of the real property comprising a public or private college, university, or other postsecondary educational institution. A person who violates this paragraph with respect to: 1. A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5. commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 2. A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 3. Any other controlled substance, except as lawfully sold, manufactured, or delivered, must be sentenced to pay a $500 fine and to serve 100 hours of public service in addition to any other penalty prescribed by law. (e) Except as authorized by this chapter, a person may not sell, manufacture, or deliver, or possess with intent to sell, manufacture, or deliver, a controlled substance not authorized by law in, on, or within 1,000 feet of a physical place for worship at which a church or religious organization regularly conducts religious services or within 1,000 feet of a convenience business as defined in s. 812.171. A person who violates this paragraph with respect to: 1. A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5. commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 2. A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 3. Any other controlled substance, except as lawfully sold, manufactured, or delivered, must be sentenced to pay a $500 fine and to serve 100 hours of public service in addition to any other penalty prescribed by law. (f) Except as authorized by this chapter, a person may not sell, manufacture, or deliver, or possess with intent to sell, manufacture, or deliver, a controlled substance in, on, or within 1,000 feet of the real property comprising a public housing facility at any time. As used in this section, the term “real property comprising a public housing facility” means real property, as defined in s. 421.03(12), of a public corporation created as a housing authority pursuant to part I of chapter 421. A person who violates this paragraph with respect to: 1. A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5. commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 2. A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 3. Any other controlled substance, except as lawfully sold, manufactured, or delivered, must be sentenced to pay a $500 fine and to serve 100 hours of public service in addition to any other penalty prescribed by law. (g) Except as authorized by this chapter, a person may not manufacture methamphetamine or phencyclidine, or possess any listed chemical as defined in s. 893.033 in violation of s. 893.149 and with intent to manufacture methamphetamine or phencyclidine. If a person violates this paragraph and: 1. The commission or attempted commission of the crime occurs in a structure or conveyance where any child younger than 16 years of age is present, the person commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. In addition, the defendant must be sentenced to a minimum term of imprisonment of 5 calendar years. 2. The commission of the crime causes any child younger than 16 years of age to suffer great bodily harm, the person commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. In addition, the defendant must be sentenced to a minimum term of imprisonment of 10 calendar years. (h) Except as authorized by this chapter, a person may not sell, manufacture, or deliver, or possess with intent to sell, manufacture, or deliver, a controlled substance in, on, or within 1,000 feet of the real property comprising a mental health facility, as that term is used in chapter 394; a health care facility licensed under chapter 395 which provides substance abuse treatment; a licensed service provider as defined in s. 397.311; a facility providing services that include clinical treatment, intervention, or prevention as described in s. 397.311(27); a recovery residence as defined in s. 397.311; an assisted living facility as defined in chapter 429; or a pain management clinic as defined in s. 458.3265(1)(a)1.c. or s. 459.0137(1)(a)1.c. A person who violates this paragraph with respect to: 1. A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5. commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 2. A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 3. Any other controlled substance, except as lawfully sold, manufactured, or delivered, must be sentenced to pay a $500 fine and to serve 100 hours of public service in addition to any other penalty prescribed by law. (i) Except as authorized by this chapter, a person commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084, and must be sentenced to a mandatory minimum term of imprisonment of 3 years, if: 1. The person sells, manufactures, or delivers, or possesses with intent to sell, manufacture, or deliver, any of the following: a. Alfentanil, as described in s. 893.03(2)(b)1.; b. Carfentanil, as described in s. 893.03(2)(b)6.; c. Fentanyl, as described in s. 893.03(2)(b)9.; d. Sufentanil, as described in s. 893.03(2)(b)30.; e. A fentanyl derivative, as described in s. 893.03(1)(a)63.; f. A controlled substance analog, as described in s. 893.0356, of any substance described in sub-subparagraphs a.-e.; or g. A mixture containing any substance described in sub-subparagraphs a.-f.; and 2. The substance or mixture listed in subparagraph 1. is in a form that resembles, or is mixed, granulated, absorbed, spray-dried, or aerosolized as or onto, coated on, in whole or in part, or solubilized with or into, a product, when such product or its packaging further has at least one of the following attributes: a. Resembles the trade dress of a branded food product, consumer food product, or logo food product; b. Incorporates an actual or fake registered copyright, service mark, or trademark; c. Resembles candy, cereal, a gummy, a vitamin, or a chewable product, such as a gum or gelatin-based product; or d. Contains a cartoon character imprint. (2)(a) Except as authorized by this chapter and chapter 499, a person may not purchase, or possess with intent to purchase, a controlled substance. A person who violates this provision with respect to: 1. A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5. commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 2. A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. 3. A controlled substance named or described in s. 893.03(5) commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083. (b) Except as provided in this chapter, a person may not purchase more than 10 grams of any substance named or described in s. 893.03(1)(a) or (1)(b), or any combination thereof, or any mixture containing any such substance. A person who violates this paragraph commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (3) A person who delivers, without consideration, 20 grams or less of cannabis, as defined in this chapter, commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083. As used in this subsection, the term “cannabis” does not include the resin extracted from the plants of the genus Cannabis or any compound manufacture, salt, derivative, mixture, or preparation of such resin. (4) Except as authorized by this chapter, a person 18 years of age or older may not deliver any controlled substance to a person younger than 18 years of age, use or hire a person younger than 18 years of age as an agent or employee in the sale or delivery of such a substance, or use such person to assist in avoiding detection or apprehension for a violation of this chapter. A person who violates this subsection with respect to: (a) A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5. commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (b) A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (c) Any other controlled substance, except as lawfully sold, manufactured, or delivered, commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. Imposition of sentence may not be suspended or deferred, and the person so convicted may not be placed on probation. (5) A person may not bring into this state any controlled substance unless the possession of such controlled substance is authorized by this chapter or unless such person is licensed to do so by the appropriate federal agency. A person who violates this provision with respect to: (a) A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5. commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (b) A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (c) A controlled substance named or described in s. 893.03(5) commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083. (6)(a) A person may not be in actual or constructive possession of a controlled substance unless such controlled substance was lawfully obtained from a practitioner or pursuant to a valid prescription or order of a practitioner while acting in the course of his or her professional practice or to be in actual or constructive possession of a controlled substance except as otherwise authorized by this chapter. A person who violates this provision commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (b) If the offense is the possession of 20 grams or less of cannabis, as defined in this chapter, the person commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083. As used in this subsection, the term “cannabis” does not include the resin extracted from the plants of the genus Cannabis, or any compound manufacture, salt, derivative, mixture, or preparation of such resin. (c) Except as provided in this chapter, a person may not possess more than 10 grams of any substance named or described in s. 893.03(1)(a), (1)(b), or (2)(b), or any combination thereof, or any mixture containing any such substance. A person who violates this paragraph commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (d) If the offense is possession of a controlled substance named or described in s. 893.03(5), the person commits a misdemeanor of the second degree, punishable as provided in s. 775.082 or s. 775.083. (e) Notwithstanding any provision to the contrary of the laws of this state relating to arrest, a law enforcement officer may arrest without warrant any person who the officer has probable cause to believe is violating the provisions of this chapter relating to possession of cannabis. (7)(a) A person may not: 1. Distribute or dispense a controlled substance in violation of this chapter. 2. Refuse or fail to make, keep, or furnish any record, notification, order form, statement, invoice, or information required under this chapter. 3. Refuse entry into any premises for any inspection or refuse to allow any inspection authorized by this chapter. 4. Distribute a controlled substance named or described in s. 893.03(1) or (2) except pursuant to an order form as required by s. 893.06. 5. Keep or maintain any store, shop, warehouse, dwelling, building, vehicle, boat, aircraft, or other structure or place which is resorted to by persons using controlled substances in violation of this chapter for the purpose of using these substances, or which is used for keeping or selling them in violation of this chapter. 6. Use to his or her own personal advantage, or reveal, any information obtained in enforcement of this chapter except in a prosecution or administrative hearing for a violation of this chapter. 7. Possess a prescription form unless it has been signed by the practitioner whose name appears printed thereon and completed. This subparagraph does not apply if the person in possession of the form is the practitioner whose name appears printed thereon, an agent or employee of that practitioner, a pharmacist, or a supplier of prescription forms who is authorized by that practitioner to possess those forms. 8. Withhold information from a practitioner from whom the person seeks to obtain a controlled substance or a prescription for a controlled substance that the person making the request has received a controlled substance or a prescription for a controlled substance of like therapeutic use from another practitioner within the previous 30 days. 9. Acquire or obtain, or attempt to acquire or obtain, possession of a controlled substance by misrepresentation, fraud, forgery, deception, or subterfuge. 10. Affix any false or forged label to a package or receptacle containing a controlled substance. 11. Furnish false or fraudulent material information in, or omit any material information from, any report or other document required to be kept or filed under this chapter or any record required to be kept by this chapter. 12. Store anhydrous ammonia in a container that is not approved by the United States Department of Transportation to hold anhydrous ammonia or is not constructed in accordance with sound engineering, agricultural, or commercial practices. 13. With the intent to obtain a controlled substance or combination of controlled substances that are not medically necessary for the person or an amount of a controlled substance or substances that is not medically necessary for the person, obtain or attempt to obtain from a practitioner a controlled substance or a prescription for a controlled substance by misrepresentation, fraud, forgery, deception, subterfuge, or concealment of a material fact. For purposes of this subparagraph, a material fact includes whether the person has an existing prescription for a controlled substance issued for the same period of time by another practitioner or as described in subparagraph 8. (b) A health care practitioner, with the intent to provide a controlled substance or combination of controlled substances that are not medically necessary to his or her patient or an amount of controlled substances that is not medically necessary for his or her patient, may not provide a controlled substance or a prescription for a controlled substance by misrepresentation, fraud, forgery, deception, subterfuge, or concealment of a material fact. For purposes of this paragraph, a material fact includes whether the patient has an existing prescription for a controlled substance issued for the same period of time by another practitioner or as described in subparagraph (a)8. (c) A person who violates subparagraphs (a)1.-6. commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083, except that, upon a second or subsequent violation, the person commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (d) A person who violates subparagraphs (a)7.-12. commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (e) A person or health care practitioner who violates the provisions of subparagraph (a)13. or paragraph (b) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084, if any controlled substance that is the subject of the offense is listed in Schedule II, Schedule III, or Schedule IV. (8)(a) Notwithstanding subsection (9), a prescribing practitioner may not: 1. Knowingly assist a patient, other person, or the owner of an animal in obtaining a controlled substance through deceptive, untrue, or fraudulent representations in or related to the practice of the prescribing practitioner’s professional practice; 2. Employ a trick or scheme in the practice of the prescribing practitioner’s professional practice to assist a patient, other person, or the owner of an animal in obtaining a controlled substance; 3. Knowingly write a prescription for a controlled substance for a fictitious person; or 4. Write a prescription for a controlled substance for a patient, other person, or an animal if the sole purpose of writing such prescription is to provide a monetary benefit to, or obtain a monetary benefit for, the prescribing practitioner. (b) If the prescribing practitioner wrote a prescription or multiple prescriptions for a controlled substance for the patient, other person, or animal for which there was no medical necessity, or which was in excess of what was medically necessary to treat the patient, other person, or animal, that fact does not give rise to any presumption that the prescribing practitioner violated subparagraph (a)1., but may be considered with other competent evidence in determining whether the prescribing practitioner knowingly assisted a patient, other person, or the owner of an animal to obtain a controlled substance in violation of subparagraph (a)1. (c) A person who violates paragraph (a) commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (d) Notwithstanding paragraph (c), if a prescribing practitioner has violated paragraph (a) and received $1,000 or more in payment for writing one or more prescriptions or, in the case of a prescription written for a controlled substance described in s. 893.135, has written one or more prescriptions for a quantity of a controlled substance which, individually or in the aggregate, meets the threshold for the offense of trafficking in a controlled substance under s. 893.135, the violation is reclassified as a felony of the second degree and ranked in level 4 of the Criminal Punishment Code. (9) The provisions of subsections (1)-(8) are not applicable to the delivery to, or actual or constructive possession for medical or scientific use or purpose only of controlled substances by, persons included in any of the following classes, or the agents or employees of such persons, for use in the usual course of their business or profession or in the performance of their official duties: (a) Pharmacists. (b) Practitioners. (c) Persons who procure controlled substances in good faith and in the course of professional practice only, by or under the supervision of pharmacists or practitioners employed by them, or for the purpose of lawful research, teaching, or testing, and not for resale. (d) Hospitals that procure controlled substances for lawful administration by practitioners, but only for use by or in the particular hospital. (e) Officers or employees of state, federal, or local governments acting in their official capacity only, or informers acting under their jurisdiction. (f) Common carriers. (g) Manufacturers, wholesalers, and distributors. (h) Law enforcement officers for bona fide law enforcement purposes in the course of an active criminal investigation. (10) If a person violates any provision of this chapter and the violation results in a serious injury to a state or local law enforcement officer as defined in s. 943.10, firefighter as defined in s. 633.102, emergency medical technician as defined in s. 401.23, paramedic as defined in s. 401.23, employee of a public utility or an electric utility as defined in s. 366.02, animal control officer as defined in s. 828.27, volunteer firefighter engaged by state or local government, law enforcement officer employed by the Federal Government, or any other local, state, or Federal Government employee injured during the course and scope of his or her employment, the person commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. If the injury sustained results in death or great bodily harm, the person commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. History.—s. 13, ch. 73-331; s. 1, ch. 76-200; s. 1, ch. 77-174; s. 2, ch. 79-1; s. 3, ch. 79-325; s. 5, ch. 80-30; s. 2, ch. 80-70; s. 490, ch. 81-259; s. 2, ch. 82-16; s. 52, ch. 83-215; s. 1, ch. 84-77; s. 5, ch. 85-242; s. 4, ch. 87-243; s. 2, ch. 88-381; s. 4, ch. 89-281; s. 1, ch. 89-524; ss. 1, 6, ch. 90-111; s. 1, ch. 93-59; s. 2, ch. 93-92; s. 1, ch. 93-194; ss. 22, 23, ch. 93-406; s. 2, ch. 96-360; s. 2, ch. 97-1; s. 1, ch. 97-43; s. 1827, ch. 97-102; s. 22, ch. 97-194; s. 106, ch. 97-264; s. 1, ch. 97-269; s. 47, ch. 97-271; s. 1, ch. 98-22; s. 1, ch. 99-154; s. 14, ch. 99-186; s. 3, ch. 2000-320; s. 11, ch. 2002-78; s. 2, ch. 2002-81; s. 3, ch. 2003-10; s. 1, ch. 2003-95; s. 2, ch. 2005-128; s. 108, ch. 2006-197; s. 2, ch. 2006-306; s. 2, ch. 2008-88; s. 6, ch. 2010-113; ss. 3, 4, ch. 2011-73; s. 2, ch. 2011-90; s. 26, ch. 2011-141; s. 2, ch. 2012-23; s. 3, ch. 2013-29; s. 153, ch. 2013-183; s. 2, ch. 2014-159; s. 1, ch. 2014-204; s. 13, ch. 2015-34; s. 5, ch. 2016-105; s. 49, ch. 2017-3; s. 5, ch. 2017-107; s. 12, ch. 2018-13; s. 107, ch. 2019-3; s. 6, ch. 2019-166; s. 124, ch. 2019-167; s. 2, ch. 2022-129; s. 1, ch. 2023-26; s. 2, ch. 2024-20; s. 13, ch. 2024-176. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d325f4425a6',t:'MTc3MDg4MjU2My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-13/"
    },
    {
      "id": "section-893131distribution",
      "number": "893.131",
      "heading": "Distribution of controlled substances resulting in overdose or serious bodily injury.",
      "text": "of controlled substances resulting in overdose or serious bodily injury.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-893132dangerous",
      "number": "893.132",
      "heading": "Dangerous fentanyl exposure of first responder resulting in overdose or serious bodily injury.",
      "text": "fentanyl exposure of first responder resulting in overdose or serious bodily injury.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-893138local",
      "number": "893.138",
      "heading": "Local administrative action to abate certain activities declared public nuisances.",
      "text": "administrative action to abate certain activities declared public nuisances.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-893146determination",
      "number": "893.146",
      "heading": "Determination of paraphernalia.",
      "text": "893.146 Determination of paraphernalia.—In determining whether an object is drug paraphernalia, a court or other authority or jury shall consider, in addition to all other logically relevant factors, the following: (1) Statements by an owner or by anyone in control of the object concerning its use. (2) The proximity of the object, in time and space, to a direct violation of this act. (3) The proximity of the object to controlled substances. (4) The existence of any residue of controlled substances on the object. (5) Direct or circumstantial evidence of the intent of an owner, or of anyone in control of the object, to deliver it to persons who he or she knows, or should reasonably know, intend to use the object to facilitate a violation of this act. The innocence of an owner, or of anyone in control of the object, as to a direct violation of this act shall not prevent a finding that the object is intended for use, or designed for use, as drug paraphernalia. (6) Instructions, oral or written, provided with the object concerning its use. (7) Descriptive materials accompanying the object which explain or depict its use. (8) Any advertising concerning its use. (9) The manner in which the object is displayed for sale. (10) Whether the owner, or anyone in control of the object, is a legitimate supplier of like or related items to the community, such as a licensed distributor of or dealer in tobacco products. (11) Direct or circumstantial evidence of the ratio of sales of the object or objects to the total sales of the business enterprise. (12) The existence and scope of legitimate uses for the object in the community. (13) Expert testimony concerning its use. History.—s. 2, ch. 80-30; s. 1445, ch. 97-102. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d34bd15e881',t:'MTc3MDg4MjU2My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-146/"
    },
    {
      "id": "section-893149unlawful",
      "number": "893.149",
      "heading": "Unlawful possession of listed chemical.",
      "text": "893.149 Unlawful possession of listed chemical.— (1) It is unlawful for any person to knowingly or intentionally: (a) Possess a listed chemical with the intent to unlawfully manufacture a controlled substance; (b) Possess or distribute a listed chemical knowing, or having reasonable cause to believe, that the listed chemical will be used to unlawfully manufacture a controlled substance. (2) Any person who violates this section commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (3) This section does not apply to a public employee or private contractor authorized to clean up or dispose of hazardous waste or toxic substances resulting from the prohibited activities listed in s. 893.13(1)(g). (4) Any damages arising out of the unlawful possession of, storage of, or tampering with a listed chemical, as defined in s. 893.033, shall be the sole responsibility of the person or persons unlawfully possessing, storing, or tampering with the listed chemical. In no case shall liability for damages arising out of the unlawful possession of, storage of, or tampering with a listed chemical extend to the lawful owner, installer, maintainer, designer, manufacturer, possessor, or seller of the listed chemical, unless such damages arise out of the acts or omissions of the owner, installer, maintainer, designer, manufacturer, possessor, or seller which constitute negligent misconduct or failure to abide by the laws regarding the possession or storage of a listed chemical. History.—s. 5, ch. 91-279; s. 3, ch. 2003-15; s. 4, ch. 2005-128; s. 35, ch. 2016-105. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d371d064b0a',t:'MTc3MDg4MjU2My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-149/"
    },
    {
      "id": "section-8931495retail",
      "number": "893.1495",
      "heading": "Retail sale of ephedrine and related compounds.",
      "text": "893.1495 Retail sale of ephedrine and related compounds.— (1) For purposes of this section, the term “ephedrine or related compounds” means ephedrine, pseudoephedrine, phenylpropanolamine, or any of their salts, optical isomers, or salts of optical isomers. (2) A person may not knowingly obtain or deliver to an individual in any retail over-the-counter sale any nonprescription compound, mixture, or preparation containing ephedrine or related compounds in excess of the following amounts: (a) In any single day, any number of packages that contain a total of 3.6 grams of ephedrine or related compounds; (b) In any single retail, over-the-counter sale, three packages, regardless of weight, containing ephedrine or related compounds; or (c) In any 30-day period, in any number of retail, over-the-counter sales, a total of 9 grams or more of ephedrine or related compounds. (3) A person may not knowingly display and offer for retail sale any nonprescription compound, mixture, or preparation containing ephedrine or related compounds other than behind a checkout counter where the public is not permitted or other such location that is not otherwise accessible to the general public. (4) A person who is the owner or primary operator of a retail outlet where any nonprescription compound, mixture, or preparation containing ephedrine or related compounds is available for sale may not knowingly allow an employee to engage in the retail sale of such compound, mixture, or preparation unless the employee has completed an employee training program that shall include, at a minimum, basic instruction on state and federal regulations relating to the sale and distribution of such compounds, mixtures, or preparations. (5)(a) Any person purchasing, receiving, or otherwise acquiring any nonprescription compound, mixture, or preparation containing any detectable quantity of ephedrine or related compounds must: 1. Be at least 18 years of age. 2. Produce a government-issued photo identification showing his or her name, date of birth, address, and photo identification number or an alternative form of identification acceptable under 8 C.F.R. s. 274a.2(b)(1)(v)(A) and (B). 3. Sign his or her name on a record of the purchase, either on paper or on an electronic signature capture device. (b) The Department of Law Enforcement shall approve an electronic recordkeeping system for the purpose of recording and monitoring the real-time purchase of products containing ephedrine or related compounds and for the purpose of monitoring this information in order to prevent or investigate illegal purchases of these products. The approved electronic recordkeeping system shall be provided to a pharmacy or retailer without any additional cost or expense. A pharmacy or retailer may request an exemption from electronic reporting from the Department of Law Enforcement if the pharmacy or retailer lacks the technology to access the electronic recordkeeping system and such pharmacy or retailer maintains a sales volume of less than 72 grams of ephedrine or related compounds in a 30-day period. The electronic recordkeeping system shall record the following: 1. The date and time of the transaction. 2. The name, date of birth, address, and photo identification number of the purchaser, as well as the type of identification and the government of issuance. 3. The number of packages purchased, the total grams per package, and the name of the compound, mixture, or preparation containing ephedrine or related compounds. 4. The signature of the purchaser, or a unique number relating the transaction to a paper signature maintained at the retail premises. (c) The electronic recordkeeping system shall provide for: 1. Real-time tracking of nonprescription over-the-counter sales under this section. 2. The blocking of nonprescription over-the-counter sales in excess of those allowed by the laws of this state or federal law. (6) A nonprescription compound, mixture, or preparation containing any quantity of ephedrine or related compounds may not be sold over the counter unless reported to an electronic recordkeeping system approved by the Department of Law Enforcement. This subsection does not apply if the pharmacy or retailer has received an exemption from the Department of Law Enforcement under paragraph (5)(b). (7) Prior to completing a transaction, a pharmacy or retailer distributing products containing ephedrine or related compounds to consumers in this state shall submit all required data into an electronic recordkeeping system approved by the Department of Law Enforcement at the point of sale or through an interface with the electronic recordkeeping system, unless granted an exemption by the Department of Law Enforcement pursuant to paragraph (5)(b). (8) The data submitted to the electronic recordkeeping system must be retained within the system for no less than 2 years following the date of entry. (9) The requirements of this section relating to the marketing, sale, or distribution of products containing ephedrine or related compounds supersede any local ordinance or regulation passed by a county, municipality, or other local governmental authority. (10) This section does not apply to: (a) Licensed manufacturers manufacturing and lawfully distributing products in the channels of commerce. (b) Wholesalers lawfully distributing products in the channels of commerce. (c) Health care facilities licensed under chapter 395. (d) Licensed long-term care facilities. (e) Government-operated health departments. (f) Physicians’ offices. (g) Publicly operated prisons, jails, or juvenile correctional facilities or private adult or juvenile correctional facilities under contract with the state. (h) Public or private educational institutions maintaining health care programs. (i) Government-operated or industry-operated medical facilities serving employees of the government or industry operating them. (11) Any individual who violates subsection (2), subsection (3), or subsection (4) commits: (a) For a first offense, a misdemeanor of the second degree, punishable as provided in s. 775.083. (b) For a second offense, a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083. (c) For a third or subsequent offense, a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084. (12) Information contained within the electronic recordkeeping system shall be disclosed in a manner authorized by state or federal law. Any retailer or entity that collects information on behalf of a retailer as required by the Combat Methamphetamine Epidemic Act of 2005 and this section may not access or use that information, except for law enforcement purposes pursuant to state or federal law or to facilitate a product recall for public health and safety. (13) A person who sells any product containing ephedrine or related compounds who in good faith releases information under this section to federal, state, or local law enforcement officers, or any person acting on behalf of such an officer, is immune from civil liability for the release unless the release constitutes gross negligence or intentional, wanton, or willful misconduct. (14) The Department of Law Enforcement shall contract or enter into a memorandum of understanding, as applicable, with a private third-party administrator to implement the electronic recordkeeping system required by this section. (15) The Department of Law Enforcement shall adopt rules necessary to implement this section. History.—s. 5, ch. 2005-128; s. 1, ch. 2010-191; s. 168, ch. 2014-17. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d39691b9be2',t:'MTc3MDg4MjU2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-1495/"
    },
    {
      "id": "section-89315rehabilitation",
      "number": "893.15",
      "heading": "Rehabilitation",
      "text": "893.15 Rehabilitation.—Any person who violates s. 893.13(6)(a) or (b) relating to possession may, in the discretion of the trial judge, be required to participate in a substance abuse services program approved or regulated by the Department of Children and Families pursuant to the provisions of chapter 397, provided the director of such program approves the placement of the defendant in such program. Such required participation shall be imposed in addition to any penalty or probation otherwise prescribed by law. However, the total time of such penalty, probation, and program participation shall not exceed the maximum length of sentence possible for the offense.",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-15/"
    },
    {
      "id": "section-893165county",
      "number": "893.165",
      "heading": "County alcohol and other drug abuse treatment or education trust funds.",
      "text": "alcohol and other drug abuse treatment or education trust funds.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-89320continuing",
      "number": "893.20",
      "heading": "Continuing criminal enterprise.",
      "text": "893.20 Continuing criminal enterprise.— (1) Any person who commits three or more felonies under this chapter in concert with five or more other persons with respect to whom such person occupies a position of organizer, a supervisory position, or any other position of management and who obtains substantial assets or resources from these acts is guilty of engaging in a continuing criminal enterprise. (2) A person who commits the offense of engaging in a continuing criminal enterprise is guilty of a life felony, punishable pursuant to the Criminal Punishment Code and by a fine of $500,000. (3) Notwithstanding the provisions of s. 948.01, with respect to any person who is found to have violated this section, adjudication of guilt or imposition of sentence may not be suspended, deferred, or withheld. (4) This section does not prohibit separate convictions and sentences for violation of this section and for felony violations of this chapter. (5) This section must be interpreted in concert with its federal analog, 21 U.S.C. s. 848. History.—s. 1, ch. 89-145; s. 25, ch. 93-406; s. 24, ch. 97-194. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d3bbb523e91',t:'MTc3MDg4MjU2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-20/"
    },
    {
      "id": "section-89321alcohol-related",
      "number": "893.21",
      "heading": "Alcohol-related or drug-related overdoses; medical assistance; immunity from arrest, charge, prosecution, and penalization.",
      "text": "or drug-related overdoses; medical assistance; immunity from arrest, charge, prosecution, and penalization.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-89330controlled",
      "number": "893.30",
      "heading": "Controlled substance safety education and awareness.",
      "text": "893.30 Controlled substance safety education and awareness.— (1) This section may be cited as the “Victoria Siegel Controlled Substance Safety Education and Awareness Act.” (2) The department shall develop a written pamphlet relating to controlled substances which includes educational information about the following: (a) Precautions regarding the use of pain management prescriptions. (b) The potential for misuse and abuse of controlled substances by adults and children. (c) The risk of controlled substance dependency and addiction. (d) The proper storage and disposal of controlled substances. (e) Controlled substance addiction support and treatment resources. (f) Telephone helplines and website links that provide counseling and emergency assistance for individuals dealing with substance abuse. (3) The department shall encourage health care providers, including, but not limited to, hospitals, county health departments, physicians, and nurses, to disseminate and display information about controlled substance safety, including, but not limited to, the pamphlet created pursuant to subsection (2). (4) The department shall encourage consumers to discuss the risks of controlled substance use with their health care providers. (5) The State Surgeon General shall make publicly available, by posting on the department’s website, the pamphlet created pursuant to subsection (2) and additional resources as appropriate. (6) The department shall fund the promotion of controlled substance safety education and awareness under this section through grants from private or federal sources. (7) The department is encouraged to collaborate with other agencies, organizations, and institutions to create a systematic approach to increasing public awareness regarding controlled substance safety. History.—s. 22, ch. 2016-212. (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'9cca7d3e1b3edfba',t:'MTc3MDg4MjU2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();",
      "history": "",
      "source_url": "https://law.justia.com/codes/florida/title-xlvi/chapter-893/section-893-30/"
    },
    {
      "id": "section-89302definitions",
      "number": "893.02",
      "heading": "Definitions. The following words and phrases as used in this chapter shall have the following meanings, unless the context otherwise requires:(1)“Administer” or “administration” means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of",
      "text": "The following words and phrases as used in this chapter shall have the following meanings, unless the context otherwise requires:(1)“Administer” or “administration” means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a person or animal.(2)“Cannabinoid receptor agonist” means a chemical compound or substance that, according to scientific or medical research, study, testing, or analysis demonstrates the presence of binding activity at one or more of the CB1 or CB2 cell membrane receptors located within the human body.1(3)“Cannabis” means all parts of any plant of the genusCannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin. The term does not include “marijuana,” as defined in s. 381.986, if manufactured, possessed, sold, purchased, delivered, distributed, or dispensed, in conformance with s. 381.986. The term does not include hemp as defined in s. 581.217 or industrial hemp as defined in s. 1004.4473.(4)“Controlled substance” means any substance named or described in Schedules I-V of s. 893.03. Laws controlling the manufacture, distribution, preparation, dispensing, or administration of such substances are drug abuse laws.(5)“Cultivating” means the preparation of any soil or hydroponic medium for the planting of a controlled substance or the tending and care or harvesting of a controlled substance.(6)“Deliver” or “delivery” means the actual, constructive, or attempted transfer from one person to another of a controlled substance, whether or not there is an agency relationship.(7)“Dispense” means the transfer of possession of one or more doses of a medicinal drug by a pharmacist or other licensed practitioner to the ultimate consumer thereof or to one who represents that it is his or her intention not to consume or use the same but to transfer the same to the ultimate consumer or user for consumption by the ultimate consumer or user.(8)“Distribute” means to deliver, other than by administering or dispensing, a controlled substance.(9)“Distributor” means a person who distributes.(10)“Department” means the Department of Health.(11)“Homologue” means a chemical compound in a series in which each compound differs by one or more repeating hydrocarbon functional group units at any single point within the compound.(12)“Hospital” means an institution for the care and treatment of the sick and injured, licensed pursuant to the provisions of chapter 395 or owned or operated by the state or Federal Government.(13)“Laboratory” means a laboratory approved by the Drug Enforcement Administration as proper to be entrusted with the custody of controlled substances for scientific, medical, or instructional purposes or to aid law enforcement officers and prosecuting attorneys in the enforcement of this chapter.(14)“Listed chemical” means any precursor chemical or essential chemical named or described in s. 893.033.(15)(a)“Manufacture” means the production, preparation, propagation, compounding, cultivating, growing, conversion, or processing of a controlled substance, either directly or indirectly, by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging of the substance or labeling or relabeling of its container, except that this term does not include the preparation, compounding, packaging, or labeling of a controlled substance by:1.A practitioner or pharmacist as an incident to his or her administering or delivering of a controlled substance in the course of his or her professional practice.2.A practitioner, or by his or her authorized agent under the practitioner’s supervision, for the purpose of, or as an incident to, research, teaching, or chemical analysis, and not for sale.(b)“Manufacturer” means and includes every person who prepares, derives, produces, compounds, or repackages any drug as defined by the Florida Drug and Cosmetic Act. However, this definition does not apply to manufacturers of patent or proprietary preparations as defined in the Florida Pharmacy Act. Pharmacies, and pharmacists employed thereby, are specifically excluded from this definition.(16)“Mixture” means any physical combination of two or more substances, including, but not limited to, a blend, an aggregation, a suspension, an emulsion, a solution, or a dosage unit, whether or not such combination can be separated into its components by physical means, whether mechanical or thermal.(17)“Nitrogen-heterocyclic analog” means an analog of a controlled substance which has a single carbon atom in a cyclic structure of a compound replaced by a nitrogen atom.(18)“Patient” means an individual to whom a controlled substance is lawfully dispensed or administered pursuant to the provisions of this chapter.(19)“Pharmacist” means a person who is licensed pursuant to chapter 465 to practice the profession of pharmacy in this state.(20)“Positional isomer” means any substance that possesses the same molecular formula and core structure and that has the same functional group or substituent as those found in the respective controlled substance, attached at any positions on the core structure, but in such manner that no new chemical functionalities are created and no existing chemical functionalities are destroyed relative to the respective controlled substance. Rearrangements of alkyl moieties within or between functional groups or substituents, or divisions or combinations of alkyl moieties, which do not create new chemical functionalities or destroy existing chemical functionalities, are allowed and include resulting compounds that are positional isomers. As used in this definition, the term “core structure” means the parent molecule that is the common basis for the class that includes, but is not limited to, tryptamine, phenethylamine, or ergoline. Examples of rearrangements resulting in creation or destruction of chemical functionalities, and therefore resulting in compounds that are not positional isomers, include, but are not limited to, ethoxy to alpha-hydroxyethyl, hydroxy and methyl to methoxy, or the repositioning of a phenolic or alcoholic hydroxy group to create a hydroxyamine. Examples of rearrangements resulting in compounds that would be positional isomers, include, but are not limited to, tert-butyl to sec-butyl, methoxy and ethyl to isopropoxy, N,N-diethyl to N-methyl-N-propyl, or alpha-methylamino to N-methylamino.(21)“Possession” includes temporary possession for the purpose of verification or testing, irrespective of dominion or control.(22)“Potential for abuse” means that a substance has properties of a central nervous system stimulant or depressant or an hallucinogen that create a substantial likelihood of its being:(a)Used in amounts that create a hazard to the user’s health or the safety of the community;(b)Diverted from legal channels and distributed through illegal channels; or(c)Taken on the user’s own initiative rather than on the basis of professional medical advice.Proof of potential for abuse can be based upon a showing that these activities are already taking place, or upon a showing that the nature and properties of the substance make it reasonable to assume that there is a substantial likelihood that such activities will take place, in other than isolated or occasional instances.(23)“Practitioner” means a physician licensed under chapter 458, a dentist licensed under chapter 466, a veterinarian licensed under chapter 474, an osteopathic physician licensed under chapter 459, an advanced practice registered nurse licensed under chapter 464, a naturopath licensed under chapter 462, a certified optometrist licensed under chapter 463, a psychiatric nurse as defined in s. 394.455, a podiatric physician licensed under chapter 461, or a physician assistant licensed under chapter 458 or chapter 459, provided such practitioner holds a valid federal controlled substance registry number.(24)“Prescription” includes any order for drugs or medicinal supplies which is written or transmitted by any means of communication by a licensed practitioner authorized by the laws of this state to prescribe such drugs or medicinal supplies, is issued in good faith and in the course of professional practice, is intended to be dispensed by a person authorized by the laws of this state to do so, and meets the requirements of s. 893.04.(a)The term also includes an order for drugs or medicinal supplies transmitted or written by a physician, dentist, veterinarian, or other practitioner licensed to practice in a state other than Florida, but only if the pharmacist called upon to fill such an order determines, in the exercise of his or her professional judgment, that the order was issued pursuant to a valid patient-physician relationship, that it is authentic, and that the drugs or medicinal supplies ordered are considered necessary for the continuation of treatment of a chronic or recurrent illness.(b)If the physician writing the prescription is not known to the pharmacist, the pharmacist shall obtain proof to a reasonable certainty of the validity of the prescription.(c)A prescription for a controlled substance may not be issued on the same prescription blank with another prescription for a controlled substance that is named or described in a different schedule or with another prescription for a medicinal drug, as defined in s. 465.003, that is not a controlled substance.(25)“Wholesaler” means any person who acts as a jobber, wholesale merchant, or broker, or an agent thereof, who sells or distributes for resale any drug as defined by the Florida Drug and Cosmetic Act. However, this definition does not apply to persons who sell only patent or proprietary preparations as defined in the Florida Pharmacy Act. Pharmacies, and pharmacists employed thereby, are specifically excluded from this definition.History.—s. 2, ch. 73-331; s. 1, ch. 75-18; s. 470, ch. 77-147; s. 1, ch. 77-174; s. 184, ch. 79-164; s. 1, ch. 79-325; s. 37, ch. 82-225; s. 169, ch. 83-216; s. 1, ch. 85-242; s. 1, ch. 91-279; s. 1, ch. 92-19; s. 1434, ch. 97-102; s. 104, ch. 97-264; s. 234, ch. 98-166; s. 300, ch. 99-8; s. 10, ch. 99-186; s. 1, ch. 2000-320; s. 3, ch. 2001-55; s. 10, ch. 2002-78; s. 13, ch. 2005-128; s. 1, ch. 2008-184; s. 18, ch. 2010-117; s. 1, ch. 2011-73; s. 12, ch. 2013-26; s. 5, ch. 2014-157; s. 1, ch. 2016-105; s. 5, ch. 2016-145; s. 18, ch. 2016-224; s. 9, ch. 2016-231; ss. 1, 10, ch. 2017-232; s. 83, ch. 2018-106; s. 2, ch. 2019-132; s. 1, ch. 2019-166; s. 2, ch. 2021-154; s. 26, ch. 2022-35; s. 3, ch. 2023-299.1Note.—Section 1, ch. 2017-232, provides that “[i]t is the intent of the Legislature to implement s. 29, Article X of the State Constitution by creating a unified regulatory structure. If s. 29, Article X of the State Constitution is amended or a constitutional amendment related to cannabis or marijuana is adopted, this act shall expire 6 months after the effective date of such amendment.” If such amendment or adoption takes place, subsection (3), as amended by s. 1, ch. 2017-232, will read:(3) “Cannabis” means all parts of any plant of the genusCannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin. The term does not include “low-THC cannabis,” as defined in s. 381.986, if manufactured, possessed, sold, purchased, delivered, distributed, or dispensed, in conformance with s. 381.986.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-tion",
      "number": "tion",
      "heading": "1, ch. 2017-232, provides that “[i]t is the intent of the Legislature to implement s",
      "text": "29, Article X of the State Constitution by creating a unified regulatory structure. If s. 29, Article X of the State Constitution is amended or a constitutional amendment related to cannabis or marijuana is adopted",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-373-methylfentanyl",
      "number": "37.3-Methylfentanyl",
      "heading": "(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide).",
      "text": "(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-383-methylthiofentanyl",
      "number": "38.3-Methylthiofentanyl",
      "heading": "",
      "text": "",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-24-methylaminorex",
      "number": "2.4-Methylaminorex",
      "heading": "(2-Amino-4-methyl-5-phenyl-2-oxazoline).",
      "text": "(2-Amino-4-methyl-5-phenyl-2-oxazoline).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-52c-b",
      "number": "5.2",
      "heading": "C-B (4-Bromo-2,5-dimethoxyphenethylamine).",
      "text": "(4-Bromo-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-225-methoxy",
      "number": "22.5-Methoxy",
      "heading": "3,4-methylenedioxyamphetamine.",
      "text": "3,4-methylenedioxyamphetamine.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-595-hydroxy-amt",
      "number": "59.5-Hydroxy-AMT",
      "heading": "(5-Hydroxy-alpha-methyltryptamine).",
      "text": "(5-Hydroxy-alpha-methyltryptamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-615-meo-mipt",
      "number": "61.5-MeO-MiPT",
      "heading": "(5-Methoxy-N-methyl-N-isopropyltryptamine).",
      "text": "(5-Methoxy-N-methyl-N-isopropyltryptamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-625-meo-amt",
      "number": "62.5-MeO-AMT",
      "heading": "(5-Methoxy-alpha-methyltryptamine).",
      "text": "(5-Methoxy-alpha-methyltryptamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-645-meo-dmt",
      "number": "64.5-MeO-DMT",
      "heading": "(5-Methoxy-N,N-dimethyltryptamine).",
      "text": "(5-Methoxy-N,N-dimethyltryptamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-655-me-dmt",
      "number": "65.5-Me-DMT",
      "heading": "(5-Methyl-N,N-dimethyltryptamine).",
      "text": "(5-Methyl-N,N-dimethyltryptamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-675-meo-dipt",
      "number": "67.5-MeO-DiPT",
      "heading": "(5-Methoxy-N,N-Diisopropyltryptamine).",
      "text": "(5-Methoxy-N,N-Diisopropyltryptamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-704-hydroxy-dipt",
      "number": "70.4-Hydroxy-DiPT",
      "heading": "(4-Hydroxy-N,N-diisopropyltryptamine).",
      "text": "(4-Hydroxy-N,N-diisopropyltryptamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-715-meo-dalt",
      "number": "71.5-MeO-DALT",
      "heading": "(5-Methoxy-N,N-Diallyltryptamine).",
      "text": "(5-Methoxy-N,N-Diallyltryptamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-742c-e",
      "number": "74.2",
      "heading": "C-E (4-Ethyl-2,5-dimethoxyphenethylamine).",
      "text": "(4-Ethyl-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-752c-t-4",
      "number": "75.2",
      "heading": "C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).",
      "text": "(4-Isopropylthio-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-762c-c",
      "number": "76.2",
      "heading": "C-C (4-Chloro-2,5-dimethoxyphenethylamine).",
      "text": "(4-Chloro-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-772c-t",
      "number": "77.2",
      "heading": "C-T (4-Methylthio-2,5-dimethoxyphenethylamine).",
      "text": "(4-Methylthio-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-782c-t-2",
      "number": "78.2",
      "heading": "C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).",
      "text": "(4-Ethylthio-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-792c-t-7",
      "number": "79.2",
      "heading": "C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).",
      "text": "(4-(n)-Propylthio-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-802c-i",
      "number": "80.2",
      "heading": "C-I (4-Iodo-2,5-dimethoxyphenethylamine).",
      "text": "(4-Iodo-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-1073-me-4-meo-mcat",
      "number": "107.3-Me-4-MeO-MCAT",
      "heading": "(3-Methyl-4-Methoxymethcathinone).",
      "text": "(3-Methyl-4-Methoxymethcathinone).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-1602c-d",
      "number": "160.2",
      "heading": "C-D (4-Methyl-2,5-dimethoxyphenethylamine).",
      "text": "(4-Methyl-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-1612c-h",
      "number": "161.2",
      "heading": "C-H (2,5-Dimethoxyphenethylamine).",
      "text": "(2,5-Dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-1622c-n",
      "number": "162.2",
      "heading": "C-N (4-Nitro-2,5-dimethoxyphenethylamine).",
      "text": "(4-Nitro-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-1632c-p",
      "number": "163.2",
      "heading": "C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).",
      "text": "(4-(n)-Propyl-2,5-dimethoxyphenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-16425i-nbome",
      "number": "164.25",
      "heading": "I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).",
      "text": "(4-Iodo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-17425b-nbome",
      "number": "174.25",
      "heading": "B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).",
      "text": "(4-Bromo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-17525c-nbome",
      "number": "175.25",
      "heading": "C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).",
      "text": "(4-Chloro-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-1885-it",
      "number": "188.5-IT",
      "heading": "(2-(1H-Indol-5-yl)-1-methyl-ethylamine).",
      "text": "(2-(1H-Indol-5-yl)-1-methyl-ethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-1896-it",
      "number": "189.6-IT",
      "heading": "(2-(1H-Indol-6-yl)-1-methyl-ethylamine).",
      "text": "(2-(1H-Indol-6-yl)-1-methyl-ethylamine).",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-241-phenylcyclohexylamine",
      "number": "24.1-Phenylcyclohexylamine",
      "heading": "",
      "text": "",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-obarbital",
      "number": "obarbital",
      "heading": "",
      "text": "",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-89307records",
      "number": "893.07",
      "heading": "Records. (1)Every person who engages in the manufacture, compounding, mixing, cultivating, growing, or by any other process producing or preparing, or in the dispensing, importation, or, as a wholesaler, distribution, of controlled substances shall:(a)On January 1, 1974, or as soon thereafter as any person f",
      "text": "(1)Every person who engages in the manufacture, compounding, mixing, cultivating, growing, or by any other process producing or preparing, or in the dispensing, importation, or, as a wholesaler, distribution, of controlled substances shall:(a)On January 1, 1974, or as soon thereafter as any person first engages in such activity, and every second year thereafter, make a complete and accurate record of all stocks of controlled substances on hand. The inventory may be prepared on the regular physical inventory date which is nearest to, and does not vary by more than 6 months from, the biennial date that would otherwise apply. As additional substances are designated for control under this chapter, they shall be inventoried as provided for in this subsection.(b)On and after January 1, 1974, maintain, on a current basis, a complete and accurate record of each substance manufactured, received, sold, delivered, or otherwise disposed of by him or her, except that this subsection shall not require the maintenance of a perpetual inventory.Compliance with the provisions of federal law pertaining to the keeping of records of controlled substances shall be deemed a compliance with the requirements of this subsection.(2)The record of controlled substances received shall in every case show:(a)The date of receipt.(b)The name and address of the person from whom received.(c)The kind and quantity of controlled substances received.(3)The record of all controlled substances sold, administered, dispensed, or otherwise disposed of shall show:(a)The date of selling, administering, or dispensing.(b)The correct name and address of the person to whom or for whose use, or the owner and species of animal for which, sold, administered, or dispensed.(c)The kind and quantity of controlled substances sold, administered, or dispensed.(4)Every inventory or record required by this chapter, including prescription records, shall be maintained:(a)Separately from all other records of the registrant, or(b)Alternatively, in the case of Schedule III, IV, or V controlled substances, in such form that information required by this chapter is readily retrievable from the ordinary business records of the registrant.In either case, the records described in this subsection shall be kept and made available for a period of at least 2 years for inspection and copying by law enforcement officers whose duty it is to enforce the laws of this state relating to controlled substances. Law enforcement officers are not required to obtain a subpoena, court order, or search warrant in order to obtain access to or copies of such records.(5)Each person described in subsection (1) shall:(a)Maintain a record which shall contain a detailed list of controlled substances lost, destroyed, or stolen, if any; the kind and quantity of such controlled substances; and the date of the discovering of such loss, destruction, or theft.(b)In the event of the discovery of the theft or significant loss of controlled substances, report such theft or significant loss to the sheriff of that county within 24 hours after discovery. A person who fails to report a theft or significant loss of a substance listed in s. 893.03(3), (4), or (5) within 24 hours after discovery as required in this paragraph commits a misdemeanor of the second degree, punishable as provided in s. 775.082 or s. 775.083. A person who fails to report a theft or significant loss of a substance listed in s. 893.03(2) within 24 hours after discovery as required in this paragraph commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083.History.—s. 7, ch. 73-331; s. 1439, ch. 97-102; s. 25, ch. 2011-141; s. 32, ch. 2016-105; s. 5, ch. 2019-166.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-89308exceptions",
      "number": "893.08",
      "heading": "Exceptions. (1)The following may be distributed at retail without a prescription, but only by a registered pharmacist:(a)Any compound, mixture, or preparation described in Schedule V",
      "text": "(b)Any compound, mixture, or preparation containing any depressant or stimulant substance described in s. 893.03(2)(a) or (c) exc",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-89309enforcement",
      "number": "893.09",
      "heading": "Enforcement. (1)The Department of Law Enforcement, all state agencies which regulate professions or institutions affected by the provisions of this chapter, and all peace officers of the state shall enforce all provisions of this chapter except those specifically delegated, and shall cooperate with all agencies ",
      "text": "(1)The Department of Law Enforcement, all state agencies which regulate professions or institutions affected by the provisions of this chapter, and all peace officers of the state shall enforce all provisions of this chapter except those specifically delegated, and shall cooperate with all agencies charged with the enforcement of the laws of the United States, this state, and all other states relating to controlled substances.(2)Any agency authorized to enforce this chapter shall have the right to institute an action in its own name to enjoin the violation of any of the provisions of this chapter. Said action for an injunction shall be in addition to any other action, proceeding, or remedy authorized by law.(3)All law enforcement officers whose duty it is to enforce this chapter shall have authority to administer oaths in connection with their official duties, and any person making a material false statement under oath before such law enforcement officers shall be deemed guilty of perjury and subject to the same punishment as prescribed for perjury.(4)It shall be unlawful and punishable as provided in chapter 843 for any person to interfere with any such law enforcement officer in the performance of the officer’s official duties. It shall also be unlawful for any person falsely to represent himself or herself to be authorized to enforce the drug abuse laws of this state, the United States, or any other state.(5)No civil or criminal liability shall be imposed by virtue of this chapter upon any person whose duty it is to enforce the provisions of this chapter, by reason of his or her being lawfully engaged in the enforcement of any law or municipal ordinance relating to controlled substances.History.—s. 9, ch. 73-331; s. 1, ch. 77-174; s. 30, ch. 79-8; s. 1441, ch. 97-102.",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-782",
      "number": "782",
      "heading": "04, relating to murder;",
      "text": "04, relating to murder;",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-784",
      "number": "784",
      "heading": "045(1)(a)2., relating to aggravated battery with a deadly weapon;",
      "text": "045(1)(a)2., relating to aggravated battery with a deadly weapon;",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-810",
      "number": "810",
      "heading": "02, relating to burglary;",
      "text": "02, relating to burglary;",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-812",
      "number": "812",
      "heading": "014, relating to theft;",
      "text": "014, relating to theft;",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-893",
      "number": "893",
      "heading": "13, relating to the unlawful distribution of controlled substances,",
      "text": "13, relating to the unlawful distribution of controlled substances,",
      "history": "",
      "source_url": ""
    },
    {
      "id": "section-89315rehabilitation",
      "number": "893.15",
      "heading": "Rehabilitation. Any person who violates s. 893",
      "text": "13(6)(a) or (b) relating to possession may, in the discretion of the trial judge, be required to participate in a substance abuse services program approved or regulated by the Department of Children and Families pursuant to the provisions of chapter 397, provided the d",
      "history": "",
      "source_url": ""
    }
  ]
}